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AMP-ACTIVATED PROTEIN KINASE REGULATION OF MYELOID ANTIGEN 
PRESENTING CELL ACTIVITY  
Kelly Casey Carroll 
December 6, 2013 
 Inflammatory and metabolic processes are critical to the survival of multicellular 
organisms. Inflammation and metabolism are closely linked, and many pathologies are 
associated with dysregulation of both of these processes, including obesity, cancer, 
diabetes, and atherosclerosis. Understanding the mechanistic links of inflammation and 
metabolism are critical for the development of treatments of metabolic and inflammatory 
diseases.  
AMP-activated protein kinase, AMPK, is a serine/threonine kinase that regulates 
energy homeostasis and metabolic stress in eukaryotes. When cellular ATP is low, 
AMPK is activated and turns off ATP-consuming anabolic pathways and turns on ATP-
generating catabolic pathways.  Previous work from our laboratory, as well as by others, 
has provided evidence that AMPKα1 acts as a negative regulator of TLR-induced 
inflammatory function. The goal of this dissertation was to investigate the role of 
AMPKα1 in myeloid antigen presenting cell activity.  
 Herein we demonstrate that AMPKα1-deficient macrophages and dendritic cells 
(DCs) exhibit heightened inflammatory function and an enhanced capacity for antigen 
presentation favoring the promotion of Th1 and Th17 responses. Macrophages and DCs 
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generated from AMPKα1-deficient mice produced higher levels of proinflammatory 
cytokines and decreased production of the anti-inflammatory cytokine IL-10 in response 
to both TLR and CD40 stimulation as compared to AMPKα1+/+ cells.   In assays of 
antigen presentation, AMPKα1 deficiency in both the myeloid APC and T cell 
populations contributed to enhanced IL-17 and IFNγ production.  Focusing on the 
CD154-CD40 interaction, we found that CD40 stimulation resulted in increased 
phosphorylation of ERK1/2, p38, and NF-κB p65 and decreased activation of the anti-
inflammatory Akt - GSK3β - CREB pathway in DCs deficient for AMPKα1. AMPKα1 
serves to attenuate LPS and CD40-mediated proinflammatory activity of myeloid APC 
and AMPKα1 activity in both APC and T cells antagonizes the development of 
proinflammatory T cell responses during antigen presentation.  
 Additionally, we sought to investigate the influence of macrophage-expressed 
AMPKα1 on tumor-macrophage interactions and macrophage polarization in the tumor 
microenvironment. Our studies show that macrophage-expressed AMPKα1 polarizes 
tumor-infiltrating macrophages (TIMs) to an anti-inflammatory phenotype and 
contributes to tumor growth. To evaluate the role of myeloid cell-expressed AMPKα1 in 
tumor growth and metastasis, we used an AMPKα1 Cre-lox transgenic mouse model. 
AMPKα1flox/flox LysM-Cre+ (described subsequently as MacAMPKα1 KO) mice had 
reduced Lewis lung carcinoma (LLC) tumor growth and metastasis compared to 
AMPKα1flox/- LysM-Cre- (WT) mice. Additionally, TIMs isolated from MacAMPKα1 
KO mice exhibited higher production of proinflammatory cytokines and matrix 
metalloproteinases (MMPs). Furthermore, TIMs isolated from MacAMPKα1 KO mice 
had higher phosphorylation of p65 NF-κB and reduced phosphorylation of Akt and 
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CREB. Overall, deficiency of myeloid AMPKα1 results in higher proinflammatory 
activity of TIMs and decreased tumor growth. 
 Our studies herein demonstrate that AMPKα1 counter-regulates myeloid cell 
TLR- and CD154-induced inflammatory activity and antagonizes the development of 
proinflammatory effector T cell responses. Furthermore, myeloid-expressed AMPKα1 
contributes to the polarization of TIMs to an anti-inflammatory phenotype and leads to 
increased tumor growth and metastasis. These studies demonstrate that AMPKα1 is an 
important link to inflammation and metabolism and is a valuable potential target for the 
treatment of inflammatory and metabolic diseases. Additionally, these studies provide 
evidence that activation of AMPKα1 in cancer therapy may contribute to increased tumor 
growth through polarization of TIMs to an anti-inflammatory phenotype, a valuable 
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In order to survive and grow, living organisms must maintain energy balance 
through regulation of consumption and generation of ATP. The AMP-activated protein 
kinase (AMPK) has been well-established as a regulator of energy homeostasis in 
eukaryotic cells. AMPK becomes activated by stresses causing ATP depletion and, once 
activated, works to turn off ATP-consuming anabolic pathways and turn on ATP-
producing catabolic pathways (Fig. 1). In recent years, AMPK has been shown to have a 
counter-regulatory role in many inflammatory processes [1]. 
 
A BRIEF HISTORY OF AMPK 
 It is estimated that the ancestral form of AMPK emerged at least one billion years 
ago [2]. In the early 1970’s, protein kinase activity associated with inactivation of acetyl-
CoA carboxylase (ACC) [3] and 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR) 
[4] were being investigated independently. Early studies of HMGR and ACC had shown 
that the kinase activity leading to inactivation of both proteins was activated by AMP and 
in 1987, Carling et al., reported that HMGR and ACC were inactivated by the same 
protein kinase [5], now known as AMPK. The name AMP-activated protein kinase was 
first proposed in 1988 by Munday et al. [6], and in 1994, mammalian AMPK was 
successfully purified and sequenced [7, 8].  
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 Since these initial studies, interest in AMPK as a regulator of cellular energy has 
grown significantly. AMPK is ubiquitously expressed in eukaryotic cells and is thought 
to have a conserved function as a metabolic sensor in all eukaryotes, mammals, fungi, 
and plants. In addition to its role in metabolism, AMPK is now considered an important 
player in inflammation and associated pathologies, including cancer, neurogenerative 
disease, obesity, and aging [1].  
 
STRUCTURE AND REGULATION OF AMPK 
Heterotrimeric structure 
AMPK is an obligate heterotrimer, made up of a catalytic α subunit and 
regulatory β and γ subunits (Fig. 1). The α and β subunits each have two isoforms (α1, 
α2, β1, β2), while the γ subunit has three (γ1, γ2, γ3). Each isoform is encoded by a 
separate gene. The subunit genes are named PRKA followed by a subunit identifier (A1, 
A2, B1, B2, G1, G2, G3); for example, the gene for the α1 subunit is PRKAA1. The 
subunit genes are distributed across five chromosomes—α1 on chromosome 5, α2 and β2 
on chromosome 1, β1 and γ1 on chromosome 12, γ2 on chromosome 7, and γ3 on 
chromosome 2 [9]. All 12 possible combinations of isoforms can form complexes, 
although α1, β1, and γ1 are the predominant isoforms in most cells [10].  
AMPK subunits show differential tissue expression and activation. AMPKα1 is 
expressed highly in murine adipose tissue, moderately in liver, kidney, heart, and brain, 
and lowest in spleen and pancreas. AMPKα2 expression in mice is highest in skeletal 
muscle, then in heart, kidney and liver, and very low in lung, brain, adipose, pancreas, 
and spleen. The AMPKβ1 subunit is expressed in many tissues, comparable to α1 subunit 
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expression, while β2 is most highly expressed in skeletal muscle and heart tissue. The 
AMPKγ1 isoform has very widespread expression, while the γ2 isoform is expressed in a 
variety of tissues including brain, placenta, and skeletal muscle, and the γ3 isoform is 
expressed rarely and mainly in skeletal muscle [9].  
It has been well-established that AMPK is activated in response to increases in the 
intracellular AMP:ATP ratio. More recently, it was discovered that in addition to AMP, 
ADP directly binds to the γ regulatory subunit and thereby induces a conformational 
change that promotes AMPK phosphorylation and protects against dephosphorylation [1]. 
The γ subunit contains two Bateman domains, sequence motifs that serve as nucleotide 
binding sites in many mammals and bacterial proteins. In the γ1 subunit, two Bateman 
domains assemble head to head to form a flattened disk with four clefts where 
nucleotides can bind. Initial studies on the γ subunit indicated that only two molecules of 
AMP bind [11], however, it was recently discovered that three of the four clefts in 
mammalian AMPKγ1 bind nucleotide [12]. One cleft does not bind nucleotide at all and 
another binds AMP very tightly and does not exc hange with ADP or ATP [12]. The 
other two sites bind AMP reversibly and competitively with ADP and ATP. Additionally, 
structural studies have shown that nucleotides bind such that the adenine moieties are 
deep within the binding cavity and the phosphate groups face the exterior and are 
partially exposed [13].  
Allosteric Regulation of AMPK 
AMPK is allosterically activated by 5’-AMP. This mechanism appears very 
specific, as only AMP and closely related AMP analogues can activate AMPK 
allosterically [1]. AMPK is not allosterically activated by ADP [1]. The presence of ATP 
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antagonizes activation by AMP, although ATP is not a direct inhibitor [14]. It is apparent 
that the degree of activation by AMP varies and is dependent upon the identity of the γ 
isoform present [15]. It is estimated that maximum allosteric activation achieves a 5-fold 
induction of AMPK activity, much less than the activation induced by phosphorylation of 
Thr172 [1].  
Regulation through phosphorylation/dephosphorylation 
AMPK activity is primarily regulated through reversible phosphorylation. In 
mammals, AMPK is only significantly active after phosphorylation of Thr172, located 
within the activation loop of the α subunit (Fig. 1) [16]. Phosphorylation of AMPK can 
be mediated by upstream kinases LKB1, CaMKK (calcium/calmodulin-dependent protein 
kinase kinase) α and β, or TAK1 (Transforming growth factor-beta (TGFβ)-activated 
kinase) [17]. Additionally, AMP and ADP promote phosphorylation of Thr172 and 
activation of AMPK [18].  
LKB1 is a serine/threonine kinase that directly phosphorylates Thr172 of AMPK 
[19-21], and studies of tissue-specific deletion of LKB1 show that it mediates the 
majority of AMPK activation [19, 20]. Although LKB1 phosphorylates only AMPKα1 
and AMPKα2 in response to energy stress, it has also been shown to phosphorylate 
twelve other kinases including those in the MARK, SIK, BRSK, and NUAK families. All 
twelve of these kinases are related to AMPK and it is generally thought that there is 
crosstalk between AMPK and the AMPK related kinases [22].  
It was believed that AMPK was only activated via an AMP-dependent mechanism 
until the discovery that CaMKKs, especially CAMKKβ, also phosphorylate AMPK at 
Thr172 [23-25]. CaMKKβ phosphorylates AMPK in response to an increase in the 
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intracellular Ca2+ concentration. Unlike LKB1, CaMKKs are tissue restricted and are 
mainly found in neurons, T cells and endothelial cells [26-28]. In addition to LKB1 and 
CaMKK, MAPKKK family member TAK1 is an upstream activator of AMPK. TAK1 
has been found to phosphorylate and activate AMPK in cell-free assays [29], but the 
contexts where TAK1 may regulate AMPK phosphorylation of Thr172 in vivo and 
whether TAK1 phosphorylation of AMPK involves LKB1 are still being explored [30]. 
The Thr172 phosphorylation site serves as an on/off switch for AMPK activity. 
While phosphorylation induces AMPK activity, dephosphorylation of AMPK leads to 
nearly complete inactivation of AMPK and it has been reported that dephosphorylated 
AMPK has negligible catalytic activity [31]. Many mammalian serine/threonine 
phosphatases have been shown to effectively dephosphorylate Thr172 and inactivate 
AMPK. These include PP (phosphoprotein phosphatase) 1, PP2A, and PP2Ca 
phosphatases, although it is apparent that the phosphatases involved in the regulation of 
AMPK may be dependent on the cell type and/or stimulus to which the cell is responding 
[32]. AMP has long been known to protect against dephosphorylation of the Thr172 
residue of AMPK. In 2011, it was shown that in addition to AMP, ADP effectively 
protects against dephosphorylation of Thr172 [33].  
The level of phosphorylation of Thr172 is controlled by the balance of activities 
of upstream kinases and protein phosphatases. There is still much to be resolved, 
including many of the structural details revealing how AMP allosterically activates 
AMPK and, along with ADP, increases phosphorylation and protects against 





Many physiological and pharmacological activators of AMPK have been 
reported. AMPK is activated by any ATP-depleting cellular stress, including nutrient 
deprivation, hypoxia, ischemia, oxidative stress and exercise [35, 36]. Additionally, 
AMPK can also be activated independently of cellular energy stress by adipose tissue 
hormones leptin and adiponectin. Leptin has been shown to activate AMPKα2 in skeletal 
muscle [37], and alternatively, inhibit AMPKα2 activity in the hypothalamus [38]. 
Adiponectin has been shown to activate AMPK in both peripheral tissues [39] and the 
hypothalamus [40]. Additionally, it is apparent that leptin and adiponectin regulation of 
AMPK in the hypothalamus mediates appetite [38]. It has also been shown that TCR 
stimulation results in activation of AMPK by CaMKK in T cells through a PI3K-
independent pathway [27]. 
Pharmacological AMPK activators include 5-aminoimidazole-4-carboxamide 
ribose (AICAR). AICAR is taken into the cell and converted to ZMP, an AMP analog 
that mimics the effects of AMP. As such, AICAR has the ability to activate any AMP-
sensitive protein, and has been shown to have AMPK-independent effects [41-43]. 
Metformin and thiazolidinediones (TZDs), both drugs used to treat type II diabetes, are 
known AMPK activators [9]. Metformin is an oral biguanide that inhibits gluconeogenic 
and lipogenic gene expression in the liver [44], and activates AMPK in an LKB1-
dependent manner [45]. It is thought that biguanides activate AMPK through mild 
inhibition of respiratory chain complex I, inhibiting mitochondrial respiration, and 
leading to a decrease in intracellular ATP levels [46]. The specific contribution of AMPK 
to the effect seen by metformin treatment, needs to be further elucidated, as one would 
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expect that reduction in mitochondrial metabolism would activate a variety of stress-
sensing pathways [17]. TZDs are insulin sensitizers and work through upregulation of 
peroxisome proliferator-activated receptors (PPARs), a group of nuclear receptors [9]. 
PPARγ is most highly expressed in adipose tissue, but has also been shown to have a 
significant role in the maintenance of skeletal muscle insulin resistance [47] and 
contributes to hepatic steatosis in liver [48]. TZDs have been shown to activate AMPK in 
skeletal muscle cells through increasing the intracellular AMP:ATP ratio [49].  
Additionally, a wide variety of plant products, termed xenobiotics, have been 
shown to activate AMPK. Resveratrol, a polyphenol found in the skin of red grapes, 
activates AMPK. Recently, low concentrations of resveratrol have been shown to lead to 
an accumulation of cAMP and activation of Epac1, a cAMP effector protein, which 
increases intracellular Ca2+ and activates AMPK via CaMKKβ [50]. In a type I diabetes 
mouse model, polyphenols were shown to activate AMPK and lower lipidemia and 
inhibit atherosclerosis disease progression [51]. Other xenobiotics that activate AMPK 
include egigallocatechin gallate found in green tea, capsaicin found in chili peppers, 
quercetin found in many fruits and vegetables, and curcumin found in tumeric. Generally, 
it is thought that these xenobiotics activate AMPK through inhibiting the respiratory 
chain or ATP synthase and may have evolved to deter insects and plant-eating animals or 
pathogens [34].  
While metformin, TZDs, and plant-derived compounds are considered indirect 
AMPK activators and often work through alteration of the AMP:ATP ratio, there are also 
several direct AMPK activators. These include the aforementioned ZMP, along with 
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A769661, PT-1, and OSU-53, and while it known that ZMP acts as an AMP mimetic, the 
mechanism for many direct activators remains elusive [1].  
 
AMPK REGULATES CARBOHYDRATE, LIPID, AND PROTEIN 
METABOLISM 
Once active, AMPK mediates many metabolic signaling events that turn off ATP-
consuming pathways and turn on ATP-generating pathways (Fig. 1). AMPK plays a 
significant role in the metabolism of carbohydrates through regulation of several 
downstream effectors. AMPK impacts expression and trafficking of GLUT4, a 
transmembrane protein that regulates the uptake of glucose across the plasma membrane 
in response to certain stimuli, such as the presence of insulin and muscle activity [52-54]. 
Constitutive activation of AMPKα1 results in increased glucose uptake in skeletal muscle 
cells [55]. AMPK also phosphorylates the insulin receptor substrate 1 (IRS-1) (Ser789), 
the most upstream component of the insulin-signaling cascade [56]. Also, AMPK, along 
with CREB-regulated transcription coactivator 2 (CRTC2), regulates liver 
gluconeogenesis [57]. AMPK phosphorylates glycogen synthase (Ser7) and inhibits its 
activity [58, 59]. Mice deficient for AMPKα2 display decreased phosphorylation (Ser7) 
of glycogen synthase in skeletal muscle basally and in response to AICAR treatment [59]. 
 Additionally, AMPK coordinates many aspects of lipid metabolism and the 
coordination of fat and carbohydrate metabolism. AMPK has a regulatory role in fatty 
acid uptake [60] and once fatty acids are taken into the cell, AMPK plays a critical role in 
determining if they are directed towards oxidation or storage [9]. AMPK phosphorylates 
and inhibits acetyl-CoA carboxylase (ACC) 1 in lipogenic tissues and mediates 
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suppression of fatty acid synthesis [2]. AMPK also suppresses fatty acid synthesis 
through inhibition of the transcription factor sterol regulatory element binding protein 1c 
(SREBP1c), which regulates many genes involved in lipogenesis, including fatty acid 
synthase (FAS) (Fig. 1) [61]. AMPK is also involved in regulation of cholesterol 
synthesis as it is directly phosphorylates (Ser872) and inhibits HMG-CoA reductase 
(HMGR) (Fig. 1), the rate-limiting enzyme for cholesterol synthesis [14, 62].  
 AMPK regulates protein synthesis through phosphorylation of eukaryote 
elongation factor 2 (eEF-2) kinase (Ser398) and results in inhibition of mRNA translation 
and peptide elongation [63]. Additionally, AMPK regulates protein synthesis through 
inhibiting the mammalian target of rapamycin complex (mTORC) 1 (Fig. 1). AMPK 
inhibition of protein synthesis has been demonstrated in skeletal muscle [64], liver [65], 
and cardiac muscle [66]. AMPK phosphorylates the tumor suppressor complex tuberous 
sclerosis complex (TSC) 2 (Ser1387), which activates the GTPase Rheb and leads to 
mTORC1 inhibition [67]. AMPK also inhibits mTORC1 activity through 
phosphorylation of raptor at Ser722 and Ser792, which makes it physically unavailable to 
the mTOR complex [68]. In addition to suppression of protein synthesis, the mTORC 
pathway has been shown to control many other aspects of metabolism, including 
regulation of glucose and lipid homeostasis, suggesting that many of the metabolic 
effects attributed to AMPK could be mediated by mTORC signaling [9]. 
 
DYSREGULATION OF AMPK IN DISEASE 
 Dysregulation of AMPK signaling is apparent in several diseases. AMPK 
regulates many pathways associated with the metabolic syndrome, a combination of 
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medical disorders characterized by insulin resistance, type 2 diabetes, cardiovascular 
disease, fatty liver disease, and dysregulation of AMPK in obesity is now being 
investigated. AMPK activity is reduced in liver, heart, and skeletal muscle of rat and 
mouse genetic models of obesity [69-71]. AICAR activation of AMPK leads to increased 
glucose uptake and fatty acid oxidation in diabetic obese rodents [72] and humans [73], 
suggesting AMPK may be a valid therapeutic target for metabolic syndrome. 
Alternatively, in a few studies of human obesity, AMPK expression and activity are not 
significantly decreased [74, 75]. Future studies will further clarify the role of AMPK 
signaling in obesity and determine if AMPK activation is a valuable therapeutic strategy 
to treat metabolic syndrome.   
AMPK has a critical role in regulation of ATP use in the heart and is thought to 
play a role in cardiovascular disease. Increased AMPK activity leads to increased glucose 
uptake [76] and fatty acid oxidation [77] in the heart, and it has been proposed that 
AMPK has a protective role against ischemia-reperfusion injury [9]. In myocardial 
ischemia, expression of AMPK α1 and α2 is elevated [77].  
 Studies thus far indicate that AMPK may play a role in aging. It has been well 
described that aging results in decreased ability to tolerate metabolic stress and increased 
AMPK signaling has been associated with longer lifespan in C. elegans [78]. The role of 
AMPK in the aging of higher organisms is not clear. Current studies show mixed results, 
as some reports indicate lower expression of AMPK in muscle with aging, while others 





AMPK AND CANCER 
LKB1, an upstream activator of AMPK, is a known tumor suppressor. Germline 
mutation in LKB1 results in Peutz-Jeghers syndrome (PJS), a rare hereditary disease 
characterized by a predisposition of benign and malignant neoplasms in various organs. 
PJS patients have a dramatically increased risk of cancer and are affected at relatively 
young ages. Although LKB1 mutations are relatively rare in most cancers, LKB1 somatic 
inactivation is seen in approximately 30-50% of sporadic lung adenocarcinomas and 19% 
of sporadic squamous cell carcinomas [79]. Additionally, it has been shown that LKB1 
expression inversely correlates with tumor grade and stage in human endometrial cancers, 
indicating that decreased expression of LKB1 may contribute to endometrial cancer 
progression [80]. 
The role of AMPK in the regulation of LKB1 tumor suppressor signaling and its 
association with cancer incidence is being investigated. AICAR treatment of MDA-MB-
231 breast cancer cells decreases proliferation, markers for invasion, and colony 
formation [81]. In vivo, AICAR treatment of MDA-MB-231 tumors in nude mice 
attenuated tumor growth [81]. AICAR has also been found to decrease the proliferative 
capacity of acute lymphoblastic leukemia cells [82].  
Much supporting evidence associating AMPK activity and decreased cancer 
incidence has been provided by studies with metformin. Diabetic patients treated with 
metformin have a nearly 30% reduction in deaths from cancer compared to those 
receiving other diabetic therapies [83]. Additionally, metformin treatment significantly 
decreased incidence, size, and increased mean latency in mammary adenocarcinomas of 
HER-2/neu-positive transgenic mice [84]. In a murine model of tobacco carcinogen-
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induced lung cancer, oral metformin treatment reduced tumor burden by >50% [85]. 
These studies along with many more concerning breast, prostate, colorectal, pancreatic, 
and other malignancies have led to over two dozen clinical trials investigating metformin 
as a potential anti-cancer drug [86]. Although the anti-tumorigenic properties of 
metformin are often attributed to its activation of the LKB1 pathway and AMPK, it is 
known that this pathway is only one of many by which metformin exerts its effects [86, 
87]. Thus, it is difficult to attribute the effects of metformin to AMPK activation alone. 
AMPK activity may suppress tumor growth through a variety of mechanisms. Tumor 
growth requires a great deal of energy and AMPK may reduce cancer cell growth through 
inhibition of anabolic pathways in times of limited energy [88].  
Alternatively, there is also evidence that AMPK activity promotes tumor growth. 
Studies on prostate cancer tissues and cell lines suggest that AMPK inhibition may 
benefit prostate cancer patients. ACC phosphorylation and AMPK activity were 
increased in malignant prostate tissue compared to normal tissue cells [89]. Reduced 
expression of AMPK through siRNA led to decreased proliferation of prostate cancer cell 
lines and treatment of prostate cancer lines with a non-selective AMPK inhibitor induced 
higher levels of apoptosis [89, 90]. It has been proposed that increased AMPK activity 
gives cancer cells a survival advantage, possibly through increasing glucose uptake and 
glycolysis, mitosis, and/or migration [1].  
 
AMPK AND INFLAMMATION 
Inflammation is crucial to maintaining health. Innate and adaptive immunity 
initiate inflammatory processes to offer protection from invading pathogens and repair 
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tissue injuries. Although inflammation is crucial to protect and heal, it can be dangerous 
if activated in excess or chronically. Chronic inflammation has been shown to play a role 
in many diseases, including type II diabetes, atherosclerosis, and cancer [1, 91].  
Inflammation and metabolism are closely linked. It is thought that these two 
systems coevolved, and in lower organisms such as Drosophila melanogaster both are 
regulated by one organ, the fat body [92]. Metabolic dysregulation is associated with 
many diseases known to have inflammatory dysregulation, including diabetes, 
atherosclerosis, and cancer [93]. Obesity is associated with chronic inflammation and 
increased risk of inflammatory disease, and alternatively, malnutrition is associated with 
immunosuppression [92]. There are also similarities between adipocytes and 
macrophages, as both cell types secrete cytokines and can be activated by pathogen 
components like LPS [92]. Additionally, pre-adipocytes can trans-differentiate into 
macrophages [92].  
It is also apparent that the metabolism of immune cells is closely related to their 
inflammatory capacity. Inflammatory cells such as activated macrophages [94] and Th17 
cells [94, 95] display high rates of glycolysis and lower rates of oxidative metabolism. 
Alternatively, anti-inflammatory macrophages [94] and regulatory T cells (Treg) [94, 95] 
have lower rates of glycolysis. It is also apparent that resting DCs generate ATP through 
oxidative phosphorylation and upon LPS stimulation, switch to glycolysis [96]. Much 
about this association is still unclear, but increased glycolysis may provide a quicker, 
albeit less efficient, source of energy for the cell to rapidly alter its functional phenotype 
from resting to inflammatory. Interestingly, the transition to glycolysis in activated cells 
mirrors the ‘Warburg effect’ previously observed in cancer cells [93].  
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AMPK has an established role in regulation of cellular energy metabolism, and 
there is a growing number of reports indicating AMPK has a prominent role in the 
regulation of inflammation. AMPK activation by AICAR has been shown to reduce the 
severity of murine acute and chronic colitis [97], experimental autoimmune 
encephalomyelitis (EAE) [98], and experimental autoimmune uveitis (EAU) [43]. 
Additionally, reports demonstrate that in vitro AICAR treatment inhibits the LPS-induced 
inflammatory response [97, 99]. AMPK activation by AICAR has also been shown to 
inhibit inducible nitric oxide synthase (iNOS) synthesis in adipocytes, macrophages, and 
myocytes [100]. AMPK activation via metformin also decreases inflammation. In mild 
metabolic syndrome, metformin reduces systemic inflammation through decreasing the 
presence of C-reactive protein and IL-6 [101]. Metformin also reduces macrophage 
migration inhibitory factor (MIF) expression in obese people [102]. Metformin is thought 
to activate AMPK through decreasing intracellular ATP through inhibition of the 
mitochondrial respiratory chain [46], but as previously described, metformin has many 
AMPK-independent effects [86, 87] and much regarding its effects on systemic 
inflammation is unknown. 
Many AMPK activators are also associated with reduced inflammation, including 
adiponectin [103], phytochemicals resveratrol and curcumin [104], as well as physical 
activity [105]. Additionally, IL-4, PPARγ agonist 15dPJG2, ciglitazone, and the green tea 
polyphenol epigallocatechin-3-gallate activate AMPK in macrophages (Suttles 
unpublished data).  
Studies from our lab using macrophage cell lines expressing constitutively active 
(CA) and dominant negative forms (DN) of AMPKα1 indicated that AMPK promotes 
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anti-inflammatory activity and suppresses proinflammatory activity in macrophages 
[106]. Macrophage cell lines expressing DN AMPKα1 produced higher levels of TNFα 
and IL-6 in response to LPS. Furthermore, we demonstrated that treatment of primary 
macrophages with anti-inflammatory stimuli such as IL-10 and TGFβ resulted in rapid 
phosphorylation of AMPK, whereas LPS stimulation resulted in rapid de-phosphorylation 
of AMPK [106]. Subsequent to this work, it was reported that AMPK counter-regulates 
lipid-induced inflammation through SIRT1 [107]. It has also been shown that AMPKβ1 
reduces adipose tissue macrophage inflammation in obesity [108]. Additionally, 
AMPKα1 antagonizes TLR-induced DC maturation [96].  It was also recently shown that 
AMPK suppresses IFNγ-induced gene expression in astrocytes and microglia [109].    
Studies on mTOR activity in macrophages have provided much insight into the 
role of AMPK in myeloid inflammation. AMPK, along with mTOR and SIRT1, has been 
shown to regulate autophagy in macrophages [110, 111]. Impairment of autophagy in 
macrophages leads to inflammation and has been associated with progression of 
atherosclerosis [112].   
AMPK has also been shown to play a role in T cell survival [113] and 
proliferation [114]. It has also been reported that AMPKα1 is required for CD8+ T cell 
memory [115]. In murine models of inflammatory disease, in vivo AICAR treatment 
reduced the production of proinflammatory Th cell cytokines [43, 97, 98].  Alternatively, 
studies by McIver et al., showed that AMPKα1 regulates T cell viability and metabolism 
and promotes CD44 expression and proinflammatory cytokine production through 
mTORC1 in CD8+ T cells, but not CD4+ T cells [116].  A study of CD4+ T cell subset 
differentiation reported that generation of Treg was accompanied by elevation of AMPK 
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activity, associated with dependency on lipid oxidation for the Treg functional phenotype 
[37].   
 
MACROPHAGE AND DC FUNCTION AND PLASTICITY 
 Macrophages and DCs are very heterogeneous and plastic cells. Both are part of 
the mononuclear phagocyte system and are generated from myeloid precursors in bone 
marrow. Newly formed monocytes leave the bone marrow, enter the blood, and populate 
different tissues and can differentiate into macrophages or DCs. Both macrophages and 
DCs have subpopulations resident to specific tissues, often given their own names such as 
microglial cells in the brain, Langerhans cells in the skin, and Kupffer cells in the liver 
[94]. It is currently not clear if all macrophages and DCs derive from a common 
progenitor and additionally, there is some controversy over whether the many varied 
subsets of macrophages and DCs arise from the same progenitor [117].     
 Macrophages are present in all tissues of the body and have an astonishing variety 
of functional and phenotypic characteristics (Fig. 2). The function and phenotype of a 
given macrophage population is thought to be dependent upon the presence of various 
factors in its environment, including cytokines, chemokines, adrenergic and cholinergic 
agonists, complement proteins, fatty acids, stress hormones, and immunoglobulins [118, 
119]. Macrophages in different tissues display quite different functional patterns. 
Stimulation by various factors alone or in combination is thought to regulate macrophage 
homing to various tissues and function. Macrophages engage in a wide spectrum of 
activities and many are in opposition to one another. These include proinflammatory and 
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anti-inflammatory activities, immunogenic and tolerogenic activities, and tissue-
destructive and tissue-restorative activities [120].  
 Many have tried to establish subsets of macrophages with distinct phenotypes. 
Macrophages are often characterized as classically activated (M1) or alternatively 
activated (M2). The M1/M2 nomenclature is derived from the T cell responses associated 
with these macrophage phenotypes. Classically activated macrophages are inflammatory 
and phagocytic and are associated with Th1 cytokines IFNγ, IL-12, TNFα and toll-like 
receptor (TLR) ligands [121]. Inflammatory macrophages have increased activity of 
STAT1 and NF-κB transcription factors that up-regulate proinflammatory genes such as 
nitric oxide and reactive oxygen species [121, 122]. Classical activation of macrophages 
is imperative to proper immune defense against viral and microbial pathogens and cancer, 
although proinflammatory activities must be tightly controlled. Dysregulation of 
macrophage-induced inflammation has been implicated in many autoimmune diseases, 
such as multiple sclerosis [123] and rheumatoid arthritis [124, 125].  
Alternatively activated macrophages display a quite different functional pattern 
and are generally anti-inflammatory and wound healing (Fig. 2). Alternative activation is 
induced by Th2 cytokines IL-4 and IL-13 and leads to production of anti-inflammatory 
IL-10, TGFβ, and arginase [126]. Alternatively activated macrophages have many 
physiologic and pathological roles and are involved in homeostasis, inflammation, repair, 
allergy, parasitic infections, and tumor progression [126, 127]. Wound healing responses 
are also associated with vascular endothelial growth factor (VEGF), MMPs, and 
epidermal growth factor (EGF) [128]. IL-4 and IL-13 signaling are also associated with 
increased expression of PPARγ, a nuclear receptor involved in wound healing and lipid 
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metabolism, and reports suggest that PPARγ expression may be involved in alternative 
activation of macrophages [128, 129]. Although classical and alternative phenotyping of 
macrophages may be helpful in some cases, in others it is limited and does not appreciate 
the apparent heterogeneity of macrophages. It is evident that exposure of macrophages to 
various stimuli alone or in combination (IL-10, TGFβ, IgG, and many others) leads to 
functional phenotypes that are not necessarily entirely classical or alternative [130].  
It is also apparent that the macrophage phenotype and response profile is not 
static. In 2003, it was reported that macrophage response to LPS changes over time, with 
vastly different gene expression early (0-6 h) and late (12-24 h) [131]. It is also clear that 
macrophages are continually sensing and responding to stimuli in their 
microenvironment. Macrophages may respond to cytokines they produced through earlier 
responses and shift their functional phenotype accordingly. In the context of injury, 
macrophages contribute early on to the generation of an inflammatory response 
(proinflammatory cytokine, antimicrobial oxidative radicals, and tissue-debriding 
proteinase production) and later once the wound is cleared of inflammatory debris, 
macrophages contribute to wound resolution [122, 130]. Although it has not been 
formally established, it is likely that the early inflammatory macrophages and late wound 
resolving macrophages are the same population experiencing a progressive change in 
their functional phenotype through differential regulation by tissue-derived cytokines, 
hormones, and metabolites [120, 130, 132]. An alternative hypothesis is that the switch in 
macrophage roles reflects a sequential recruitment of first inflammatory then healing 
populations of macrophages [121]. More studies are needed to elucidate the mechanisms 
regulating macrophage injury response and resolution.  
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Studies in our lab also demonstrated that macrophages revert back to their original 
phenotype after cytokine signaling ends. For example, in vitro or in vivo treatment of 
macrophages with cytokine changes their functional response to LPS. However, if the 
macrophages are washed after cytokine treatment and cultured for 1-2 days without 
cytokine, they respond to LPS stimulation identically to macrophages that had no 
cytokine stimulation [130]. Additionally, when immature DCs, bone marrow-derived 
macrophages, and peritoneal macrophages are removed from IL-4 and GM-CSF and 
placed in a neutral environment, they revert back to a basal macrophage phenotype [130, 
133]. These studies and others indicate that cytokines induce a transient functional 
pattern rather than a stable macrophage subset.  
Macrophage populations in various tissues throughout the body (i.e. lung, liver, 
peritoneum, brain) are usually considered to be separate lineages with distinct and unique 
functions [118, 119]. Early studies indicated that many of these populations were derived 
from precursors that seeded organs during development. Since then, however, it has been 
shown that the slow turnover of tissue macrophage populations is maintained, at least in 
part, by infiltrating monocytes from the blood [118, 119]. Although each of these 
populations displays a unique phenotype, usually described by high/low expression of 
various cell surface markers, it is apparent that there is still much heterogeneity within 
each population. Importantly, each population is also able to alter its phenotype in 
response to infection and/or inflammation [118, 119, 134]. These observations have led 
many to question how much of the phenotype of a macrophage population is a result of 
reversible adaptation to the tissue microenvironment and how much of the phenotype is 
due to irreversible differentiation [130].  
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 DCs are highly specialized APC that efficiently activate T lymphocytes (Fig. 3).  
DCs arise from precursors in the blood and home to peripheral non-lymphoid tissues as 
immature DCs. Immature DCs sense and sample antigen in their environment through 
forming and retracting processes from the cell body, and are often present at sites where 
antigen exposure is more intense. These sites include those at the body surface and 
internal mucosae [135]. Immature DCs express MHC molecules, low levels of 
costimulatory molecules, and chemokine receptors. In the presence of pathogens and 
inflammation, immature DCs become activated and mature. Once mature, DCs increase 
expression of MHC molecules and chemokine receptors and have an increased ability to 
secrete cytokines and chemokines [136]. Up-regulation of chemokine receptors directs 
mature DC migration to lymphoid organs where they drive various effector T cell 
responses. Importantly, in absence of pathogenic and inflammatory signals, DCs promote 
tolerance through inhibition of T cell reactions, specifically through clonal deletion of 
inflammatory T cells and expansion of Tregs [135, 136].  
Like macrophages, DCs are very heterogeneous and display plasticity. They do 
not exist as one distinct population, but as an assembly of many subpopulations. Subsets 
of DCs have been identified in lymphoid and non-lymphoid tissues. DCs are classified 
into two main subsets: conventional myeloid derived DCs and plasmacytoid DCs. 
Plasmacytoid DCs are crucial to antiviral immune responses and selectively express 
TLR7 and TLR9 and large amounts of Type I IFN in both mice and humans [135]. This 
dissertation discusses myeloid-derived DCs, a very heterogeneous group of cells 
expressing myeloid markers, specifically CD11c, CD13, CD33, CD11b, and MHC II in 
humans [137].  
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Being very heterogeneous, DCs within the same species and even in different 
regions of the same organ can vary in their surface expression of certain markers, 
phagocytic and endocytic ability, MHC and costimulatory molecule expression, and 
cytokine secretion. DCs can be stimulatory or regulatory in nature and there are many 
intermediate phenotypes. Stimulatory DCs are characterized by IL-12, TNFα, IFNα, and 
IL-6 cytokines and drive Th1, Th2 and Th17 responses [135]. Alternatively, regulatory 
DCs are characterized by IL-10, TGFβ, indoleamine 2, 3-dioxygenase (IDO), and 
arginase and drive Treg responses [137]. The functional phenotype of DCs is determined 
by environmental stimuli, very similar to the determination of macrophage functional 
phenotype. Additionally, there seems to be some overlap between macrophages and 
myeloid DCs. In response to macrophage colony-stimulating factor (M-CSF), myeloid 
DCs from blood develop a macrophage morphology [138]. Diao et al. also reported that 
immunostimulatory DCs evolve into macrophage-like cells with a regulatory phenotype 
during cancer [139]. 
DCs play a critical role at the interface of innate and adaptive immunity and 
therefore it is not surprising that they are involved in the pathology of many diseases. 
While stimulatory DCs are important in pathogen clearance and tumor 
immunosurveillance, they have also been associated with autoimmunity. It has been 
shown that the tolerogenic function of DCs is compromised in many autoimmune 
diseases [137], including psoriasis [140], systemic lupus erthyematosus (SLE) [141], 
allergy [142], and inflammatory bowel disease [143]. Additionally, tolerogenic DCs can 
be exploited by tumors to maintain a tumor-promoting immunosuppressive environment 
and also by pathogens, leading to chronic infection [137].  
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Because macrophages and DCs display a wide variety of phenotypes and can be 
both immunostimulatory and immunosuppressive, much interest has been generated in 
the cellular mechanisms that determine their functional phenotype. Identifying and 
manipulating pathways that govern macrophage and DC functional phenotype is a 
promising therapeutic strategy. Specifically, through the presence or absence of various 
stimuli, stimulatory macrophages and DCs may be able to be transformed into regulatory 
cells and vice versa. Diseases that are characterized by macrophage and DC-driven 
chronic inflammation (i.e. autoimmunity) could be treated with therapeutics that drive a 
regulatory macrophage and DC functional phenotype. Alternatively, diseases that are 
characterized by macrophage and DC-driven immunosuppression, like cancer, could be 
treated through transforming these cells to a more immunostimulatory and anti-tumor 
phenotype [120]. 
Our lab is interested in the mechanisms that govern DC and macrophage behavior 
and through studies on fatty acid binding proteins, we became interested in AMPK as a 
mediator of macrophage and DC inflammatory activity. Knowing AMPK has regulatory 
roles in metabolism and inflammation, we wanted to investigate the role of AMPK in the 
regulation of antigen presentation activity and TIM activity. Herein, we demonstrate that 
AMPKα1 counter-regulates APC LPS and CD40-induced inflammatory activity and that 
deficiency in AMPKα1 in both APC and T cells promotes Th1 and Th17 responses. 
Additionally, we report that deficiency of myeloid AMPKα1 leads to reduced tumor 







Figure 1. AMPK turns off ATP-consuming pathways and turns on ATP-generating 
pathways. AMPK is a heterotrimeric serine/threonine kinase that is made up of a 
catalytic α subunit, β scaffolding subunit, and γ regulatory subunit. AMPK senses the 
cellular AMP+ADP:ATP ratio through binding of nucleotides to the γ regulatory subunit 
and is allosterically activated by AMP. AMPK is activated by upstream kinases through 
phosphorylation of the α subunit at Thr172. Once active, AMPK turns off ATP 
consuming pathways such as those involved in the synthesis of fatty acids, sterols, and 











Figure 2. Macrophages have a wide variety of functions. Macrophages have the ability 
to perform a wide variety of activities, many in opposition to one another. Macrophages 
can exhibit proinflammatory activities such as secretion of proinflammatory cytokines, 
chemokines, and metabolites. Additionally, macrophages can secrete anti-inflammatory 
cytokines, like IL-10 and TGFβ. Macrophages can also contribute to wound resolution 










Figure 3. APC present antigen to naïve T cells. APC phagocytose antigen at the sites 
of infection, such as the skin, and then travel to lymphoid organs, where they display 
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 APC are crucial to the development of specific immune responses that are 
appropriate to different types of pathogens. It is well-reported that APC direct the 
generation of inflammatory and tolerogenic immune responses. APC traffic through 
peripheral tissues, sampling antigens from their microenvironment [135]. In the steady 
state, much of the antigen sampled by APC is from apoptotic tissue cells during turnover 
and is critical in the maintenance of self-tolerance and does not activate APC or induce 
inflammation [144-146]. During infection, however, APC increase their MHC and 
costimulatory molecule expression and migrate from the periphery to secondary 
lymphoid organs where they display pathogenic antigens to naïve T cells and drive 
effector T cell responses (Fig. 3) [135]. Migration of APC from peripheral tissues to 
secondary lymphoid organs is initiated through changes in chemokine receptor and 
adhesion molecule expression on the APC [147].  
 Through presentation of antigen to naïve T cells, APC signal important 
information. Through pathogen-derived antigenic peptides bound to MHC, APC trigger 
the T-cell receptor and confer the molecular identity of the pathogen. Through CD80 and 
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CD86, APC provide a costimulatory second signal and indicate the pathogenic nature of 
the antigen. Both the antigen-specific signal and costimulatory signals must be present to 
activate antigen specific naïve T cells into effector and memory cells [148]. Additionally, 
APC confer a “third signal” that contributes to the polarization of the T cell response. 
APC are capable of driving a wide variety of T cell responses. Those of CD4+ T helper 
(Th) are particularly varied and generally characterized by the cytokines they produce. 
CD4+ Th subsets include Th1, Th2, Th17, and Treg. The type of T cell response 
generated is dependent on a number of factors including the presence of pathogen 
associated molecular patterns and cytokines in the microenvironment, level of 
costimulation, and interactions with other immune cells [149-152]. When intracellular 
pathogens (i.e. bacteria, viruses, fungi) are present, APC produce IL-12 and type I IFN  
and drive CD4+ T cells to differentiate into Th1 cells that secrete IFNγ (Fig. 4). 
Alternatively, the presence of extracellular pathogens such as helminths induces APC to 
drive Th2 responses characterized by secretion of IL-4, IL-5, and IL-13. Th17 responses 
are driven in the presence of IL-1β, IL-6, IL-23, and TGFβ and are characterized by 
RORγT, IL-17, IL-21, and IL-23 production. Naïve CD4+ T cells are polarized to a Treg 
phenotype when TGFβ and retinoic acid are present and result in the production of IL-10 
and TGFβ [153]. Traditionally, Th subsets have been viewed as terminally differentiated 
cells with a defined phenotype, but in recent years it has become apparent that some Th 
subsets can display plasticity and phenotypic flexibility [154]. Specifically, Th17 and 
Treg subsets display phenotypic flexibility, while Th1 and Th2 subsets change their 
functional phenotype much less readily [155].    
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CD40 is a transmembrane glycoprotein surface receptor and a member of the 
tumor necrosis factor receptor (TNFR) family that is very important in antigen 
presentation. CD40 is expressed constitutively on both DCs and macrophages and is also 
expressed on monocytes, B cells, and endothelial cells [94, 156]. Binding of CD40 by its 
counter-receptor, CD154 (also known as TRAP, T-BAM, CD40 Ligand, or CD40L), has 
been shown to induce changes in DC that make them more effective APC, including 
increased expression of MHC II as well as costimulatory molecules CD80 and CD86 
[157]. CD40 ligation has also been shown to condition DCs for effective cytotoxic T 
lymphocyte induction [158-160]. Additionally, CD40 signaling in DCs and macrophages 
has been shown to induce production of proinflammatory cytokines and chemokines [94, 
156, 157]. CD154 is expressed by activated CD4+ T cells, on many other cell types, and 
in soluble form and the CD40:CD154 interaction mediates both APC and T cell 
responses (Fig. 4) [94, 156].  
 Given the reports by our lab and others demonstrating that AMPK is an important 
regulator of macrophage [106-109], DC [96], and T cell inflammatory responses [113-
116], we investigated the role of AMPKα1 in antigen presentation. Herein, we utilized 
AMPKα1 knockout mice to analyze the role of AMPKα1 in APC function and T cell-
APC interactions, including the unexplored role of AMPKα1 in CD40 signaling. Herein, 
we demonstrate that AMPKα1 polarizes APC to an anti-inflammatory phenotype and 
attenuates LPS and CD40-induced proinflammatory activity. Additionally, deficiency of 
AMPKα1 in both APC and T cells results in enhanced capacity for production of 
proinflammatory T cell responses. 
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MATERIALS AND METHODS 
 
Mice. Mice deficient for AMPKα1 were generated as described previously [161] 
and provided by Dr. Leona Rubin, University of Missouri, with permission of Dr. Benoit 
Viollet.  AMPKα1-deficient and wild-type littermates are bred and maintained in the 
University of Louisville’s Research Resources Facility. All animal care and experimental 
procedures were approved by the University of Louisville’s Institutional Animal Care 
and Use Committee. 
Reagents. LPS (Escherichia coli serotype O111:B4) was purchased from Sigma-
Aldrich. CD40 was activated with FLAG-tagged multimeric CD154 (MegaCD40L™) 
purchased from Enzo Life Sciences. CD3 was activated with plate-bound LEAF™ anti-
CD3 antibody (clone 17A2) (Biolegend). Western blot detection of specific proteins used 
the following primary Abs: anti-phospho-AMPKα (Thr172), anti-AMPKα, anti-phospho-
ERK1/2 (Thr202/Tyr204), anti-ERK1/2, anti-phospho-NF-κB p65 (Ser536), anti-NF-κB 
p65, anti-phospho-p38 MAPK (Thr180/Tyr182), anti-p38 MAPK, anti-phospho-GSK3β 
(Ser9), anti-GSK3β, anti-phospho-CREB (Ser133), anti-CREB, anti-phospho-Akt 
(Ser473), anti-Akt (Cell Signaling Technology), anti-β-actin, and HRP-conjugated 
secondary Ab (Jackson ImmunoResearch Laboratories). 
ELISA. Murine bone marrow-derived DCS and macrophages were generated as 
described previously [162]. Following stimulation in 96 well plates, supernatants were 
collected and assayed by ELISA for TNFα, IL-6, IL-10, IFNγ (BD Biosciences), and IL-
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17 (R&D Systems) according to the manufacturer’s instructions. Analysis was performed 
using an E-max precision micro plate reader (Molecular Devices).  
Ag Presentation Assays. Murine bone marrow-derived DCs and macrophages 
were plated (105 cells/well in 100 µL medium) with 100 µg/mL OVA peptide (Sigma 
Aldrich) for 4 h. T cells isolated from spleens of OT-II mice (The Jackson Laboratory) 
using CD4 (L3T4) Microbeads (Miltenyi Biotec) were then added to culture. 
Supernatants were collected after 48 h and analyzed via ELISA.  
Myelin oligodendrocyte glycoprotein peptide, MOG35–55, corresponding to the 
sequence MEVGWYRSPFSRVVHLYRNGK was purchased from Bio-Synthesis. Mice 
were injected in the flank with 100 µl of an emulsion containing 150 µg of MOG35–55 in 
CFA (Sigma-Aldrich) supplemented with 500 ng of Mycobacterium tuberculosis H37Ra 
(Difco Laboratories). Fourteen days later, T cells were isolated from the spleens of 
immunized mice using Pan T Cell Isolation Kit II (Miltenyi Biotec). 2.5 x 105 T cells 
were added to murine bone marrow DCs and macrophages that had been pulsed with 50 
µg/mL MOG35–55 peptide for 1 h. Supernatants were collected and assayed by ELISA at 
48 h.  
Flow cytometry. Single cell suspensions of bone marrow-derived DCs and 
macrophages were stained with fluorescently conjugated antibodies against murine 
CD11b, CD11c, CD80, CD86, CD40, and MHC II I-Ab (all from BD Biosciences) for 30 
min at 4°C, washed, and analyzed using a FACSCalibur flow cytometer and FlowJo 
software (Tree Star). CD4+ T cells were isolated from spleens of wild-type mice using 
CD4 (L3T4) Microbeads (Miltenyi Biotec) and were stained with fluorescently 
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conjugated antibodies against murine CD4 and CD154 (both from BD Biosciences) and 
analyzed using the same method. 
Phagocytosis Assay. Murine bone marrow-derived DCs and macrophages were 
cultured for 24 h with IgG FITC-conjugated latex beads (Cayman Chemical). Cells were 
collected, stained with fluorescently conjugated antibodies against CD11c or CD11b 
(both from BD Biosciences) for 30 min at 4°C, washed, and analyzed using a 
FACSCalibur flow cytometer and FlowJo software (Tree Star). 
Western blot analysis. Murine bone marrow-derived DCs and macrophages, and 
splenic CD4+ T cells were lysed in buffer containing 125 mM Tris (pH 6.8), 2% SDS, 
20% glycerol, 200 uM PMSF, protease inhibitor mixture (Promega), and phosphatase 
inhibitor mixture (ThermoFisher Scientific). Total protein content of the samples was 
assessed by BCA protein assay (ThermoFisher Scientific). Equal amounts of protein were 
separated on 10% Criterion gels (Bio-Rad) by SDS-PAGE. Proteins were transferred to 
nitrocellulose membranes using the Trans-blot Turbo Transfer System (Bio-Rad). Ab-
bound proteins were detected using an ECL Western blotting analysis system (GE 
Healthcare), and the membranes were exposed to UltraCruz 5x7 Autoradiography Film 
(Santa Cruz Biotechnology) Densitometric analysis was performed using UN-SCAN-IT 
gel analysis software (Silk Scientific).  
Statistical Analysis. Statistical significance between groups was evaluated by 
two way analysis of variance (ANOVA) followed by Bonferroni multiple comparison test 








AMPKα1 activity counter-regulates APC inflammatory activity  
 The influence of AMPKα1 on APC inflammatory activity was evaluated using 
bone marrow-derived DCs and macrophages generated from AMPKα1-deficient mice. 
Cytokine production of AMPKα1-deficient bone marrow-derived DCs and macrophages 
in response to LPS stimulation was measured by ELISA. AMPKα1-deficient APC 
showed increased LPS-induced production of the proinflammatory cytokines IL-6 (Fig. 5 
A, D) and TNFα (Fig. 5 B, E). Alternatively, decreased production of the anti-
inflammatory cytokine IL-10 was displayed by AMPKα1-deficient APC stimulated with 
LPS (Fig. 5 C, F). The results of these experiments reveal that AMPKα1 counter-
regulates LPS-induced inflammatory cytokine production in primary macrophages and 
DCs and support our previous work that utilized macrophage cell lines transfected with 
DN and CA forms of AMPKα1 [106]. 
 
AMPKα1-deficient APC promote proinflammatory Th cell responses 
 To determine the influence of AMPKα1 on T cell-APC interactions, bone 
marrow-derived DCs and macrophages generated from AMPKα1 knockout mice were 
pulsed with OVA and cocultured with OT-II T cells. Cell culture supernatants were 
assayed for cytokine content. AMPKα1-deficient APC induced significantly higher levels 
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of T cell production of IFNγ (Fig. 6 A, C) and IL-17 (Fig. 6 B, D) than wild-type APC, 
demonstrating that absence of AMPKα1 in APC leads to a promotion of Th1 and Th17 
responses.  
 We also evaluated APC-T cell interactions using T cells isolated from mice 
immunized with MOG35–55 peptide. We verified that bone marrow-derived DCs and 
macrophages, along with CD4+ splenic T cells from AMPKα1-deficient mice did not 
express AMPK (Fig. 7). AMPKα1-deficient and AMPKα1+/+ APC were pulsed with 
MOG35–55 peptide and co-cultured with splenic CD4+ T cells harvested from 
AMPKα1+/+ and AMPKα1-/- mice that had been immunized with MOG35–55 14 d earlier.  
AMPKα1-deficient APC induced significantly higher levels of IFNγ (Fig. 8 A, C) and IL-
17 (Fig. 9 A, C) secretion than AMPKα1+/+ APC.  
Assays utilizing AMPKα1-deficient T cells provided evidence for the role of 
AMPKα1 in the regulation of effector T cell responses. In assays with AMPKα1+/+ 
APC, T cells isolated from AMPKα1-/- mice led to increased production of IFNγ (Fig. 8 
B, D) and IL-17 (Fig. 9 B, D). AMPKα1-deficiency in both cell types may promote Th1 
and Th17 responses. When both APC and T cells were deficient in AMPKα1 the most 
profound influence on production of IFNγ (Fig. 8 B, D) and IL-17 (Fig. 9 B, D) was 
observed. T cells were isolated from total body AMPKα1-/- mice, and it is important to 
consider the effect of T cell priming by AMPKα1-/- APCs in immunized mice before 
they were isolated and used in our recall assay. This is addressed further in the Chapter 1 
discussion. Additionally, we observed no difference in CD154 expression of AMPKα1-




APC deficiency of AMPKα1 leads to increased expression of CD80 and CD86  
To further explore the role of AMPKα1 in antigen presentation, the impact of 
AMPKα1-deficiency on expression of antigen presentation machinery was evaluated. 
LPS-stimulated AMPKα1-deficient DCs had significantly higher expression of 
costimulatory molecules CD80 (Fig. 11 A-E) and CD86 (Fig. 12 A-E) compared to DCs 
generated from control mice. AMPKα1-deficiency in LPS-stimulated macrophages 
resulted in similar increases of CD80 (Fig. 11 A-E) and CD86 (Fig. 12 A-E), but did not 
reach statistical significance. We did not see a significant difference in CD40 (Fig. 13) or 
MHC II (Fig. 14) expression on AMPKα1-deficient bone marrow-derived DCs or 
macrophages compared to those generated from control mice, nor did we see differences 
in phagocytosis of latex beads (Fig. 15).  
 
AMPKα1 regulates APC response to CD154 stimulation 
 The CD40:CD154 interaction is critical to productive APC-T cell interactions [94, 
156]. With the demonstration that AMPKα1 influences antigen presentation and the 
development of effector T cell responses, we investigated the response of myeloid APC 
to CD154 stimulation. AMPKα1-deficient bone marrow-derived DCs and macrophages 
were generated and evaluated for their cytokine production in response to stimulation 
with a soluble, multimeric CD154. AMPKα1-deficient APC displayed increased 
production of the proinflammatory cytokine IL-6 in response to CD154 stimulation (Fig. 
16 A, C) and alternatively, decreased production of the anti-inflammatory cytokine IL-10 
(Fig. 16 B, D). In contrast to previous observations by our laboratory and others that 
proinflammatory stimuli result in decreased phosphorylation of AMPKα1 [96, 106, 107, 
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163], stimulation of macrophages and DCs with CD154 at a concentration that effectively 
induced a proinflammatory response (1.0 µg/mL) had no effect on phosphorylation of 
AMPKα1 (Fig. 17). 
 We considered a number of downstream targets of AMPK as possible mediators 
of the anti-inflammatory activity we observed. CD154-mediated TRAF signaling 
activates the NF-κB and MAPK pathways, including p38 and ERK1/2 kinases [109, 164-
168]. We evaluated CD154-induced NF-κB activation through phosphorylation of p65. 
As shown in Fig. 18A, CD154 induced p65 phosphorylation in AMPKα1-deficient DCs 
to a much greater degree than in DCs generated from wild-type mice.  Phosphorylation of 
the MAPKs ERK1/2 and p38, which have been implicated in the production of 
proinflammatory cytokines in response to CD40 activation [109, 166, 168], was also 
evaluated.  AMPKα1-deficient DCs showed much higher phosphorylation of ERK1/2 and 
p38 in response to CD154 stimulation (Fig. 18 B,C) 
AMPKα1 is known as a modulator of signaling events downstream of the PI3K-
Akt pathway [169] and in previous studies of macrophage function we found that 
deficiency of AMPKα1 resulted in decreased Akt activity in response to LPS-stimulation 
[106]. In the unphosphorylated state GSK3β is active and prevents IL-10 expression via 
its inactivation of the transcription factor CREB.  Akt can phosphorylate and inactivate 
GSK3β (Ser9) such that it can no longer prevent CREB-dependent IL-10 production 
[170, 171].   We evaluated phosphorylation of Akt, CREB, and GSK3β in AMPKα1-
deficient DCs. As shown in Fig. 19 A-C, DCs lacking AMPKα1 expression displayed 
decreased phosphorylation of Akt, CREB, and GSK3β when stimulated with CD154 as 





Figure 4. The CD40:CD154 interaction induces proinflammatory activity in 
macrophages and T cells. Binding of CD40, expressed on macrophages, to its counter-
receptor, CD154, on T cells results in macrophage production of proinflammatory 
proteins and cytokines, such as IL-12, IL-6, and monocyte chemoattractant protein 
(MCP) -1. Production of IL-12 results in the development of Th1 effector T cells. 
Additionally, the CD40:CD154 engagement results in T cell IFNγ production, which 











Figure 5. AMPKα1 modulates the inflammatory response of DCs and macrophages. 
Bone marrow-derived DCs (A-C) and macrophages (D-F) were generated from 
AMPKα1-/- and AMPKα1+/+ mice and stimulated with LPS at the concentrations shown 
for 18 h or left unstimulated. IL-6, TNFα, and IL-10 levels were detected by ELISA. Data 
are shown as mean ± SEM and are combined results of three independent experiments (*, 






Figure 6. Ag presentation by AMPKα1-/- DCs and macrophages promotes 
proinflammatory T cell responses. AMPKα1+/+ and AMPKα1-/- bone marrow-derived 
DCs (A-B) and macrophages (C-D) were pulsed with OVA and coincubated with OT-II 
CD4+ T cells for 18 h. IFNγ and IL-17 levels were detected by ELISA. Data are shown as 





Figure 7. AMPKα1-/- macrophages, DCs, and T cells do not express AMPKα. Bone 
marrow-derived macrophages and DCs were generated from AMPKα1+/+ and AMPKα1-
/- mice. T cells were isolated from spleens of AMPKα1+/+ and AMPKα1-/- mice. After 
cell lysis, Western blot was performed with Abs against AMPKα and β-actin. 
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Figure 8. AMPKα1 deficiency in both APC and T cells leads to Th1 responses. Bone 
marrow-derived DCs and macrophages were generated from AMPKα1-deficient and 
AMPKα1+/+ mice. DCs (A-B) and macrophages (C-D) were pulsed with MOG35–55 
before coculture with T cells from MOG35–55-immunized AMPKα1+/+ (A, C) or 
AMPKα1-/-  (B, D) mice. Levels of IFNγ were detected by ELISA. Data shown are mean 









Figure 9. AMPKα1 deficiency in both APC and T cells leads to Th17 responses. 
Bone marrow-derived DCs and macrophages were generated from AMPKα1-deficient 
and AMPKα1+/+ mice. DCs (A-B) and macrophages (C-D) were pulsed with MOG35–55 
before coculture with T cells from MOG35–55-immunized AMPKα1+/+ (A, C) or 
AMPKα1-/-  (B, D) mice. Levels of IL-17 were detected by ELISA. Data shown are 
mean ± SD and are representative of three independent experiments with similar results 





Figure 10. AMPKα1-deficient T cells do not display altered CD154 expression. 
Surface expression of CD154 on AMPKα1+/+ and AMPKα1-/- splenic T cells was 
analyzed via flow cytometry. CD154 expression of unstimulated cells (A-B) and cells 
stimulated with plate-bound anti-CD3 antibody (2.5 µg/mL) for 18 h (C-D) was 
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evaluated. Histograms show fluorescence of CD154 expression (black line) of CD4+ T 
cells and unstained cells (solid grey peak). Mean fluorescence intensity (MFI) of 
populations in brackets is stated numerically. Data shown in A-D are representative of 
three independent experiments with similar results. Bar graphs (E) describe fold change 
in MFI of CD154 compared to unstimulated wild-type cells and values are mean ± SEM 








Figure 11. AMPKα1-deficient APC have increased expression of CD80. Surface 
expression of CD80 on AMPKα1+/+ and AMPKα1-/- bone marrow-derived DCs and 
macrophages was analyzed via flow cytometry. Costimulatory molecule expression of 
unstimulated cells (A, B) and cells stimulated with LPS (100 ng/mL) for 18 h (C, D) was 
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evaluated. Histograms show fluorescence of CD80 expression (black line) of CD11c+ 
(for DCs) or CD11b+ (for macrophages) cells and unstained cells (solid grey peak). Mean 
fluorescence intensity (MFI) of populations in brackets is stated numerically. Data shown 
in A-D are representative of three independent experiments with similar results. Bar 
graphs (E) describe fold change in MFI of CD80 compared to unstimulated wild-type 
cells and values are mean ± SEM and are the combined results of three independent 






Figure 12. AMPKα1-deficient APC have increased expression of CD86. Surface 
expression of CD86 on AMPKα1+/+ and AMPKα1-/- bone marrow-derived DCs and 
macrophages was analyzed via flow cytometry. CD86 expression of unstimulated cells 
(A, B) and cells stimulated with LPS (100 ng/mL) for 18 h (C, D) was evaluated. 
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Histograms show fluorescence of costimulatory molecule expression (black line) of 
CD11c+ (for DCs) or CD11b+ (for macrophages) cells and unstained cells (solid grey 
peak). Mean fluorescence intensity (MFI) of populations in brackets is stated 
numerically. Data shown in A-D are representative of three independent experiments with 
similar results. Bar graphs (E) describe fold change in MFI of CD86 compared to 
unstimulated wild-type cells and values are mean ± SEM and are the combined results of 





Figure 13. AMPKα1-deficiency does not alter APC CD40 expression. Surface 
expression of CD40 on AMPKα1+/+ and AMPKα1-/- bone marrow-derived DCs and 
macrophages was analyzed via flow cytometry. CD40 expression of unstimulated cells 
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(A-B) and cells stimulated with LPS (100 ng/mL) for 18 h (C-D) was evaluated. 
Histograms show fluorescence of CD40 expression (black line) of CD11c+ (for DCs) or 
CD11b+ (for macrophages) cells and unstained cells (solid grey peak). Mean 
fluorescence intensity (MFI) of populations in brackets is stated numerically. Data shown 
in A-D are representative of three independent experiments with similar results. Bar 
graphs (E) describe fold change in MFI of CD40 compared to unstimulated wild-type 








Figure 14. AMPKα1-deficient APC do not have altered expression of MHC II. 
Surface expression of MHC II on AMPKα1+/+ and AMPKα1-/- bone marrow-derived 
DCs and macrophages was analyzed via flow cytometry. MHC II expression of 
unstimulated cells (A-B) and cells stimulated with LPS (100 ng/mL) for 18 h (C-D) was 
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evaluated. Histograms show fluorescence of MHC II expression (black line) of CD11c+ 
(for DCs) or CD11b+ (for macrophages) cells and unstained cells (solid grey peak). Mean 
fluorescence intensity (MFI) of populations in brackets is stated numerically. Data shown 
in A-D are representative of three independent experiments with similar results. Bar 
graphs (E) describe fold change in MFI of MHC II compared to unstimulated wild-type 







Figure 15. AMPKα1-deficiency does not alter APC phagocytosis of latex beads. 
AMPKα1+/+ and AMPKα1-/- bone marrow-derived DC and macrophage phagocytosis 
of latex beads was analyzed via flow cytometry. FITC+ latex bead fluorescence of 
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unstimulated cells (A-B) and cells stimulated with LPS (100 ng/mL) for 18 h (C-D) was 
evaluated. Histograms show fluorescence of FITC expression (black line) of CD11c+ (for 
DCs) or CD11b+ (for macrophages) cells and unstained cells (solid grey peak). Mean 
fluorescence intensity (MFI) of populations in brackets is stated numerically. Data shown 
in A-D are representative of three independent experiments with similar results. Bar 
graphs (E) describe fold change in MFI of FITC compared to unstimulated wild-type 


















Figure 16. AMPKα1 regulates the inflammatory cytokine response of APC to 
CD154 stimulation. Bone marrow-derived DCs (A-B) and macrophages (C-D) were 
generated from AMPKα1-/- and AMPKα1+/+ mice and stimulated with CD154 at the 
concentrations shown for 18 h or left unstimulated. IL-6 and IL-10 cytokine levels were 
detected by ELISA. Data shown are mean ± SEM and are the combined results of three 









Figure 17. CD154 stimulation of DCs and macrophages has no effect on 
phosphorylation of AMPKα. Bone marrow-derived DCs (A) and macrophages (B) 
generated from AMPKα1+/+ mice were stimulated with 1.0 µg/mL CD40L for the 
timepoints indicated. After cell lysis, Western blot was performed using Abs against p-
AMPK (Thr172) and total AMPK. Data shown are representative of four independent 




Figure 18. AMPKα1 expression modulates CD40-induced NF-κB, ERK1/2, and p38 
signaling in DCs. Bone marrow-derived DCs were generated from AMPKα1-/- and 
AMPKα1+/+ mice and stimulated with 1.0 µg/mL CD154 for the time points indicated. 
After cell lysis, Western blot was performed using Abs against p-NF-κB p65 (Ser536) 
and total NF-κB p65 (A), p-ERK1/2 (Thr202/Tyr204) and total ERK1/2 (B), and p-p38 
MAPK (Thr180/Tyr182) and p38 MAPK (C). Bands were analyzed by densitometry and 
displayed as bar histograms. Data shown are representative of three (B, C) and four (A) 




Figure 19. AMPKα1 expression modulates CD40-induced Akt- CREB- GSK3β 
signaling in DCs. Bone marrow-derived DCs were generated from AMPKα1-/- and 
AMPKα1+/+ mice and stimulated with 1.0 µg/mL CD154 for the time points indicated. 
After cell lysis, Western blot was performed using Abs against p-Akt (Ser473) and total 
Akt (A), p-CREB (Ser133) and total CREB (B), and p-GSK3β (Ser9) and total GSK3β 
(C). Bands were analyzed by densitometry and displayed as bar histograms. Data shown 






AMPK has been recognized recently as a counter-regulator of inflammatory 
pathways including those induced by TLR and IFNγ stimulation [96, 106, 163] and fatty 
acids [107, 108].  Our previous work utilizing macrophage cell lines transfected with CA 
and DN forms of AMPKα1, as well as AMPKα1 siRNA knock down, revealed 
AMPKα1’s role as a negative regulator of TLR-mediated inflammatory activity [106]. In 
this report, use of primary myeloid APC generated from AMPKα1-deficient mice 
confirms the function of AMPKα1 in the suppression of TLR-mediated induction of 
proinflammatory cytokine production and the enhancement of anti-inflammatory IL-10 
production (Fig. 5) and establishes AMPKα1 as a regulator of APC activity and CD40 
signal transduction (Figs. 18-19).  These data suggest that the influence of AMPK 
activators on development of autoimmune disease in mice [43, 98] could be largely due 
to AMPKα1’s regulatory role in the outcome of CD154:CD40 interactions during initial 
APC events as well as during T cell activation of myeloid cells at the sites of 
inflammation. 
We investigated a number of downstream effectors of AMPKα1 to determine the 
mechanism by which AMPKα1 exerts its anti-inflammatory influence on CD40 signaling 
including the Akt-GSK3β pathway known to be suppressive of TLR-mediated 
inflammatory signaling [170, 171]. Previous reports on the association of AMPK and Akt 
activation have shown mixed results, with some suggesting that AMPK activation is 
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positively correlated with Akt activation and others reporting an association of AMPK 
activity with decreased Akt activity (reviewed in Ref. [169]). We have previously shown 
a positive association of AMPKα1 and Akt in macrophages stimulated with LPS [106]. 
Likewise, in the present study, AMPKα1-deficient DCs responded to CD154 stimulation 
with decreased Akt activity, enhanced GSK3β activity, and decreased CREB activation 
(Fig. 19 D-F).  
Akt must be phosphorylated at two sites to become active: Thr308 by 
phosphoinositide-dependent kinase I (PDK1) [172, 173] and Ser473 by the mTOR 
complex (mTORC) 2 [174]. When cellular energy becomes low, AMPK phosphorylates 
and activates TSC2, an inhibitor of mTOR [67] and alternatively Akt can phosphorylate 
and inactivate TSC2, thereby activating mTORC1 [175, 176]. mTORC1 regulates mRNA 
translation in part through phosphorylation and activation of S6K1 [177], which has been 
shown to phosphorylate and inactivate GSK3β [178]. This fits with our data showing that 
decreased AMPK activity is associated with decreased Akt phosphorylation (Ser473) and 
decreased phosphorylation (Ser9) of GSK3β in CD154-stimulated DCs (Fig. 19 A, C).  
GSK3β is a negative regulator of the transcription factor CREB, and 
phosphorylation and inactivation of GSK3β enhances CREB activity [170, 171].  It is 
thought that inhibition of GSK3β allows CREB to compete for the nuclear coactivator 
protein CREB-binding protein, which is required for NF-κB activity.  This results in 
reduced NF-κB activation and enhanced expression of CREB-activated IL-10 synthesis 
[171].  Accordingly, we observe decreased CREB phosphorylation (Fig. 19B) and 
increased phosphorylation of p-65 NF-κB (Fig. 18A) in AMPKα1-deficient DCs 
stimulated with CD154. AMPKα1-deficient DCs and macrophages also have increased 
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NF-κB production of proinflammatory cytokines and decreased synthesis of IL-10 in 
response to TLR- and CD154-stimulation (Fig. 5 and 16). 
Our studies herein indicate that deficiency of AMPK has no effect on the 
phagocytosis of latex beads (Fig. 16). This result is in contrast to a previous report 
showing activation of AMPK via AICAR and metformin increases macrophage 
phagocytosis of apoptotic cells and bacteria [179]. As previously described, AICAR and 
metformin have AMPK-independent effects and thus it is possible the observed increase 
in phagocytic activity was independent of AMPK.  
We also found that absence of AMPK in APC led to increased expression of 
CD80 and CD86 (Fig. 11-12). It has been previously reported that treatment of DCs with 
AICAR and LPS results in an AMPKα1-independent decrease in expression of CD80, 
CD86, CD40, and MHC II I-Ab [43]. Although AICAR has many AMPKα1-independent 
effects, our results demonstrate that AMPKα1 activity is involved in the regulation of 
CD80 and CD86 expression (Fig. 11-12). The increased presence of CD80 and CD86 
costimulatory molecules in AMPKα1-deficient APC is associated with a robust induction 
of Th1 and Th17 responses (Fig. 6, 8-9).  
In addition to AMPKα1 expression by APC, we demonstrate a role for T cell-
expressed AMPKα1 in the development of Th immune responses (Fig. 8-9). Previous 
reports on the role of AMPK in CD4+ T cells show mixed results. One study implicated 
AMPKα1 in the regulation of inflammatory cytokine production by CD8+ T cells, but not 
CD4+ T cells [116]. A requirement for AMPK activity for Treg function has been 
reported [37]. It has also been shown that in vivo AICAR treatment in a murine model of 
EAU resulted in decreased CD4+ Th1 and Th17 T cell responses [43]. Our results fit with 
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the latter studies, wherein absence of AMPKα1 in CD4+ T cells leads to development of 
proinflammatory T cell responses (Figs. 11-12).  
It is very important to note that in our studies of T-cell expressed AMPKα1, T 
cells were isolated from MOG35-55-immunized total body AMPKα1-/- mice and 
restimulated with AMPKα1+/+ and AMPKα1-/- bone marrow-derived APCs pulsed with 
MOG35-55 peptide.  Because the T cells were taken from total body AMPKα1-/- knockout 
mice, they may have been primed by AMPKα1-/- DCs before we isolated them from the 
spleen and utilized them in our recall assay. It is therefore difficult to determine from this 
experiment the extent to which T cell AMPKα1-deficiency led to higher production of 
proinflammatory cytokines compared to the potential effect of priming by an AMPKα1-
deficient APC.  
Excessive proinflammatory T cell responses are associated with autoimmune disease, 
including rheumatoid arthritis, and therapeutic strategies include targeting factors that can 
dampen these T cell responses. Our results indicate that AMPKα1 is one such potential 
target, as AMPKα1 expression in APC leads to reduced IFNγ and IL-17 T cell production 
in antigen presentation assays (Figs. 6, 8-9). Additionally, there are several therapeutic 
strategies that may benefit from inhibition of AMPK and activation of a proinflammatory 
DC response. Tolerogenic DCs are an obstacle to the success of DC vaccine 
immunotherapy and inhibition of AMPK may increase DC proinflammatory activity and 
result in a more effective vaccine. Although this has not yet been tested to our 
knowledge, AMPK inhibition in myeloid cells may lead to a greater immune response 
against pathogenic microbes, parasites, etc. Additionally, an immunosuppressive 
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environment perpetuates cancer pathology and inhibition of AMPKα1 to activate a 



















 More men and women die from cancer of the lung than that of any other tissue 
[180]. Nearly 80% of lung malignancies are non-small cell lung cancers (NSCLC), which 
have a grim prognosis. Only 15% of patients survive five years beyond diagnosis with 
NSCLC. It is widely accepted that chronic cigarette smoke is the largest contributor to 
lung cancer development, however it is not the only factor involved, as many chronic 
smokers do not develop cancer and, alternatively, lung cancer arises in nonsmokers, 
although rarely [181]. Being such a common and deadly disease, there is much interest in 
the development of new therapeutics for lung cancer.  
 Inflammatory processes have been shown to be highly involved in cancer 
development and progression. Chronic inflammation has been identified as a significant 
player in the development of many cancers and treatment with anti-inflammatory drugs 
has been shown to reduce cancer risk [182]. In conditions of chronic inflammation, it is 
evident that persistent recruitment of immune cells leads to higher production of reactive 
nitrogen and oxygen species, creates a mutagenic environment, and induces 
transformation of proximal epithelial cells. Additionally, chronic inflammation creates an 
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environment rich in growth factors and cytokines that may induce premalignant cell 
proliferation and survival [183]. Many inflammatory pathways are suspected to 
contribute to lung cancer development. NF-κB signaling, in particular, is thought to play 
a major role [184]. There is some degree of immune cell infiltration in all tumors, with 
some tumors displaying minimal infiltration and others much heavier [185]. Although 
some reports indicate that infiltrating immune cells can be involved in eradication of 
tumors, it is apparent that many infiltrating cells are supportive of tumor growth and 
metastasis [186]. TIMs, in particular, have been shown to be involved in tumor-
supporting immune activities.  
 
TUMOR-INFILTRATING MACROPHAGES 
Monocytes are actively recruited to tumors from the bloodstream through the 
expression of various chemokines by malignant and stromal cells in tumors [186]. These 
include macrophage colony stimulating factor (M-CSF), MCP-1, CCL2, CCL3, CCL4, 
CCL5, CCL8, and VEGF [187]. VEGF is a major chemoattractant for monocytes and 
macrophages, and it is evident that more macrophages are found in VEGF-positive 
human breast carcinomas than those negative for VEGF [188, 189]. CXCL12 has also 
been shown to attract monocytes and macrophages to tumors, and has been linked to their 
recruitment to hypoxic areas of tumors [190].  
The accumulation of macrophages and monocytes in tumors has been long-
associated with poor prognosis in many cancers. Over 80% of studies published correlate 
a high density of TIMs with grim prognosis [191]. These include cancers of the breast, 
prostate, endometrium, bladder, kidney, and esophagus, along with squamous cell 
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carcinoma and follicular lymphoma [186]. Alternatively, there are some cancers where 
high numbers of TIMs correlate with a favorable prognosis, including stomach, 
colorectal, and melanoma [186]. It was originally thought that infiltrating immune cells 
were involved in the generation of an anti-tumor response, and indeed, macrophages from 
healthy or inflamed tissues display an ability to lyse malignant cells, present tumor 
antigens, and produce proinflammatory cytokines stimulating anti-tumor T cell and NK 
cell activities [186]. Although macrophages are capable of generating anti-tumor 
immunity, those isolated from tumors both in human and animal models, do not display 
these activities. Instead, TIMs display an “alternative” functional phenotype associated 
with enhanced anti-inflammatory cytokine expression, promotion of angiogenesis, and 
poor antigen presentation capability [192]. In response to an immunosuppressive tumor 
microenvironment, TIMs are subverted by the tumor and have been shown to promote 
tumor angiogenesis, invasion, metastasis, and generalized immunosuppression in the 
tumor microenvironement [120, 186]. Even within the tumor, macrophages display 
significant heterogeneity, and functional phenotypes are generally attributed to the 
discrete microenvironments of different areas of the tumor [120].   
Macrophages are recruited to hypoxic and necrotic areas of the tumor and it is 
apparent that conditions there immobilize them, leading to significant accumulation of 
macrophages in these regions. TIMs near blood vessels are involved in tumor cell 
invasion and metastasis. TIMs produce a number of pro-angiogenic cytokines, such as 
TNFα and IL-8, growth factors like VEGF and basic fibroblast growth factor (bFGF), and 
enzymes including MMP-2, MMP-7, MMP-9, MMP-12, and COX-2 [193]. These 
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angiogenic factors are likely responsible for the correlation observed between increased 
TIM accumulation and high vascular grade of many cancers [194, 195].  
It has been demonstrated that macrophages assist tumor cell migration away from 
the main body of the tumor and extravasation into blood vessels [120]. The coordination 
of tumor cell and macrophage activities seems to be dependent upon EGF and CSF-1 
signaling, respectively, as inhibition of either pathway blocks mobilization of both cell 
types [196, 197]. Macrophages induce tumor cell migration through expression of 
chemoattractants like EGF. In response to triggering of the EGFR, tumor cells secrete 
CSF-1, attracting macrophages and inducing them to secrete EGF [183]. An EGF/CSF-1 
paracrine loop is thought to have a major role in metastasis, supported by clinical reports 
indicating CSF-1 expression in tumor cells and EGF expression in macrophages are both 
indicators of poor prognosis [198, 199]. Studies of human breast and bone cancer have 
also indicated that CSF-1 expression is associated with increased metastasis [200].  
In addition to coordination of tumor cell escape from the primary tumor, 
macrophages aid in the establishment of metastases at distant sites. In a breast cancer 
mouse model, systemic depletion of macrophages resulted in reduced lung metastasis 
[201]. It is also evident that alveolar macrophage and endothelial cell expression of 
MMP-9 and VEGF is necessary for the colonization and growth of tumor cells in the lung 
[202]. Studies indicating that macrophages at metastatic sites support tumor formation are 
supported by clinical evidence that high counts of macrophages in regional lymph node 
metastases are associated with decreased patient survival [203].  
Macrophages have also been implicated in the establishment and maintenance of 
the immunosuppressive tumor microenvironment. Several reports indicate that tumor-
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derived cytokines, growth factors, proteases, and chemokines influence macrophage 
phenotype and function within the tumor [204-206]. Tumor-derived factors such as IL-4, 
IL-6, IL-10, and TGFβ inhibit cytotoxic activity of macrophages in the tumor [204, 207]. 
Several of these mediators have also been shown to reduce macrophage MHC II 
expression and are thought to inhibit presentation of tumor-associated antigens to T cells, 
and anti-tumor immunity [204]. TIMs display suppressed IL-12 production, a cytokine 
involved in NK and T cell cytotoxic responses [208]. Hypoxia within the tumor likely 
contributes to immunosuppressive macrophage activity, as it impairs the development of 
immune cells from their precursors and the anti-tumor functions of any immune cells that 
are formed [204, 209]. Additionally, hypoxia suppresses macrophage phagocytosis of 
dead and dying cells and expression of the costimulatory molecule CD80, further 
suppressing anti-tumor activities [204, 209, 210]. Generally, TIMs are strongly polarized 
towards anti-inflammation by tumor-derived factors and play a large role in the 
subversion of many kinds of anti-tumor immunity. 
Peritumor and distal macrophages produce prostaglandin E2, TGFβ, and IL-10 
[204] and are thought to spread immunosuppression from the site of the tumor and 
provoke systemic immune suppression. Macrophages in various tissues display an 
immunosuppressive phenotype regardless of the presence or absence of metastases [204, 
211]. Although the mechanism by which the primary tumor induces immunosuppression 
in distal macrophages has not been elucidated, it has been shown that tumors release 
microvesicles expressing various ligands and cytokines. These microvesicles are 
suspected to not only generate an immunosuppressive functional phenotype in 
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macrophages, but also downregulate NK cell activity, prevent maturation of myeloid DCs 
and the generation of anti-tumor T cell immune responses [212].  
In addition to macrophages, immature myeloid cells called myeloid-derived 
suppressor cells (MDSC) accumulate in the tumor and play an important role in 
immunosuppression. In mice, MDSC are Gr1+CD11b+ and are subtyped as granulocytic 
MDSC (G-MDSC) characterized by a CD11b+Gr1hiLy6G+Ly6Clow/medCD49d- phenotype 
and monocytic MDSC (M-MDSC) characterized by a CD11b+Gr1midLy6G-
Ly6ChiCD49d+ phenotype. It has been observed that tumor expansion of MDSC is mostly 
restricted to G-MDSC in the majority of tumor models [213]. MDSC suppress T cell 
responses through a variety of mechanisms, including production of reactive oxygen 
species [213]. MDSC also promote activation and expansion of Treg [214], downregulate 
macrophage IL-12 production [215], and induce antigen specific tolerance of CD8+ [216] 
and possibly CD4+ [217] T cell responses .  
The strong immunosuppression established through MDSC and TIMs is a major 
obstacle in the development of cancer therapeutic strategies [218]. It has been shown that 
macrophages from healthy and inflamed tissues can generate potent anti-tumor responses, 
and remarkably, several reports have demonstrated that TIMs can be induced to display 
anti-tumor cytotoxic activities [219-223]. Studies indicate that increasing the presence of 
IL-12 [219, 223], induction of CD40 signaling [221, 222], and depletion of IL-10 [220] 
may be effective ways of altering immunosuppressive TIMs to generate cytotoxic 
activities. Reprogramming macrophages to reduce or eliminate their support for tumor 
angiogenesis, invasion, and metastasis and enhance their support for anti-tumor NK and 
T cell cytotoxic adaptive responses is a promising therapeutic strategy [120]. 
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Previous studies from our lab [106] along with those described herein (Chapter 2) 
indicate that AMPKα1 is a counter-regulator of myeloid inflammatory activity. LPS and 
CD40 stimulation of AMPKα1-deficient macrophages results in increased 
proinflammatory cytokine production and decreased production of the anti-inflammatory 
cytokine IL-10 [Figs. 5 and 16 and Ref. [106]. Additionally, it is apparent that absence of 
AMPKα1 in both macrophages and DCs results in promotion of Th1 and Th17 responses 
(Figs. 6, 8-9) and increased expression of costimulatory molecules CD80 and CD86 
(Figs. 11-12). Having demonstrated that absence of AMPKα1 results in a 
proinflammatory myeloid functional phenotype, we wanted to investigate the role of 
macrophage-expressed AMPKα1 on tumor-macrophage interactions and macrophage 
polarization in the tumor microenvironment. Herein, we utilize an AMPKα1 Cre-lox 
transgenic mouse model to determine the effect of myeloid-expressed AMPKα1 on LLC 
tumor growth and metastasis. We found that decreased AMPKα1 expression amplified 











MATERIALS AND METHODS 
 
Mice. AMPKα1flox/flox LysM-Cre+ (MacAMPKα1 KO) mice were generated 
through crossing LoxP AMPKα1 mice, provided by Benoit Viollet, with LysM-Cre mice 
(The Jackson Laboratory). AMPKα1flox/flox LysM-Cre+ (MacAMPKα1 KO) and 
AMPKα1flox/- LysM-Cre- (WT) mice are bred and maintained at the University of 
Louisville Research Resources Facility. All animal care and experimental procedures 
used in this study were approved by the University of Louisville’s Institutional Animal 
Care and Use Committee.  
Tumor model. LLC tumor tissues were generated as previously described [224] 
and provided by Dr. Chi-Ping Day at the National Cancer Institute (Bethesda, Maryland). 
Tumor tissues were thawed, gently dissociated with a scalpel, and cultured in vitro to 
produce a viable cell line. Tumors were then maintained by in vivo passage with limited 
intermittent culture in vitro. Tumor cells (2 x 105) were injected subcutaneously into the 
right flank of MacAMPKα1 KO and WT mice. Five to seven mice were used in each 
group. Tumors were measured every 2-3 days with calipers at two bisecting diameters 
and an approximate volume was calculated by the formula (long side x short side2) x 6/π. 
Mice were sacrificed after 18 days.  
To prepare single cell suspensions, resected tumors were digested using a tumor 
dissociation kit (Miltenyi Biotec) and MACS tissue dissociator (Miltenyi Biotec). The 
resulting cell suspensions were filtered through 70µm cell strainers (BD Biosciences) and 
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washed with 5% FBS in RMPI 1640. Tumor-infiltrating CD11b+ cells were isolated by 
positive selection with anti-CD11b (Mac-1) magnetic beads (Miltenyi Biotec). A purity 
of >95% CD11b+ cells was confirmed by flow cytometry.  
Flow Cytometric Analysis. Single cell suspensions were stained with 
fluorescently conjucated antibodies against murine CD4, CD8, CD19, CD11c, CD11b, 
F4/80, and NK1.1 (all from BD Biosciences) for 30 minutes at 4ºC, washed, and 
analyzed using a FACSCalibur flow cytometer and FlowJo software (Tree Star Inc.). A 
sample of 10,000 cells was isolated from each tumor and the number of positively stained 
cells in the sample was determined and expressed as a percentage. The calculated 
percentage was multiplied by the total number of tumor cells to determine the number of 
positively stained cells in the tumor.  
Quantitative Real-time RT-PCR analysis. mRNA was isolated from 106 
purified TIMs and converted to cDNA using MACS One-Step cDNA Columns (Miltenyi 
Biotec). Real-time RT-PCR was performed with a DNA-Opticon 3 Monitor (Bio-Rad) 
using SYBR Green (Qiagen). IL-6, TNFα, IL-23, and MMP-12 expression was analyzed 
by Quantitect Primer Assays (Qiagen). Results were normalized to β-actin. Relative 
expression of RNA transcripts was quantified using the Relative Expression Software 
Tool, REST.  
Western blot analysis. 106 macrophages were lysed in buffer containing 125 mM 
Tris (pH 6.8), 2% SDS, 20% glycerol, 200 uM PMSF, protease inhibitor mixture 
(Promega), and phosphatase inhibitor mixture (ThermoFisher Scientific). Total protein 
content of the samples was assessed by BCA protein assay (ThermoFisher Scientific). 
Equal amounts of protein were separated on 10% Criterion gels (Bio-Rad) by SDS-
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PAGE. Proteins were transferred to nitrocellulose membranes using the Trans-blot Turbo 
Transfer System (Bio-Rad). Ab-bound proteins were detected using an ECL Western 
blotting analysis system (GE Healthcare), and the membranes were exposed to UltraCruz 
5x7 Autoradiography Film (Santa Cruz Biotechnology). Densitometric analysis was 
performed using UN-SCAN-IT gel analysis software (Silk Scientific). 
Statistical Analysis. Statistical significance between groups was evaluated as 
indicated by unpaired t test or two way analysis of variance (ANOVA) followed by 
Bonferroni multiple comparison test using Graphpad Prism software (Graphpad, La Jolla, 









Deficiency of myeloid cell-expressed AMPKα1 results in decreased rate of tumor 
growth and metastasis.  
To determine the role of myeloid cell-expressed AMPKα1 in tumor growth, we 
utilized an AMPKα1 Cre-lox transgenic mouse model. Previous studies demonstrated the 
predominant expression of LysM in the myeloid lineage [225], and AMPKα1flox/flox 
LysM-Cre+ (MacAMPKα1 KO) mice have myeloid-specific deficiency in AMPKα1. 
MacAMPKα1 KO and WT mice were subcutaneously injected in the flank with LLC 
tumor cells. Caliper measurements of tumor volume (Fig. 20) indicated that 
MacAMPKα1 KO mice had reduced tumor growth compared to WT mice through 18 
days post-injection. Tumors harvested at day 18 from MacAMPKα1 KO mice weighed 
less than those from WT mice (Fig. 21). We also wanted to evaluate the role of myeloid 
cell-expressed AMPKα1 on lung metastasis. MacAMPKα1 KO mice had a lower number 
of lung metastases (Fig. 22).  
As decreases in body weight can indicate muscle wasting and severe illness, we 
periodically weighed mice throughout the experiment. Both MacAMPKα1 KO
74 
 
and WT mice maintained weight throughout the course of tumor growth, indicating that 
tumor burden did not result in muscle wasting (Fig. 23).  
 
MacAMPKα1 KO mice have increased CD19+ and decreased CD8+ immune cell 
infiltration of primary tumors  
  It has been well-established that immune cells infiltrate tumors, including 
macrophages, natural killer (NK) cells, CD4+ and CD8+ T cells, B cells, and DCs. We 
wanted to determine the degree of infiltration of various immune cells into primary 
tumors of MacAMPKα1 KO and WT mice. We evaluated immune cell infiltration as a 
percentage of a sample of 10,000 tumor cells (Fig. 24A) and the number of infiltrating 
immune cells in the total tumor (Fig. 24B).  
The percentage of infiltrating cells expressing CD19+, a B cell marker, was 
significantly increased in tumors from MacAMPKα1 KO mice compared to WT (Fig. 
24A). The number of infiltrating CD19+ B cells in the tumor was also increased in tumors 
from MacAMPKα1 KO mice compared to WT, but the difference was not significant 
(Fig. 24B). Additionally, the number of infiltrating CD8+ T cells was significantly 
decreased in tumors from MacAMPKα1 KO mice, compared to those from WT mice 
(Fig. 24B). The percentage of CD8+ T cells in tumors from MacAMPKα1 KO mice was 
decreased compared to tumors from WT mice, but the difference was not significant (Fig. 
24A). Expression of NK cell (Ly6G/NK1.1), CD4+ T cell, macrophage (F4/80/CD11b), 
and DC (CD11c) markers of single cell suspensions from MacAMPKα1 KO primary 
tumors was similar to those from WT tumors (Fig. 24), indicating that deficiency of 
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AMPKα1 in myeloid cells does not impact the infiltration of these immune cell 
populations in the tumor. 
 
TIMs from MacAMPKα1 KO mice have increased expression of proinflammatory 
mediators 
 The immunosuppressive tumor microenvironment has been associated with 
increased tumor growth and invasion, and macrophages drive this pathology [120]. As 
deficiency in AMPKα1 has been shown to lead to proinflammatory activity in 
macrophages [106, 107, 163], we wanted to characterize TIMs in tumors of 
MacAMPKα1 KO mice.  We first verfied that TIMs isolated from MacAMPKα1 KO 
mice had dramatically reduced expression of phosphorylated and total AMPK compared 
to control mice (Fig. 25).  
 TIMs isolated from MacAMPKα1 KO mice had higher mRNA expression of 
proinflammatory cytokines IL-6, TNFα, and IL-23 compared to WT mice (Fig. 26). 
Additionally, MacAMPKα1 KO mice had significantly higher expression of MMP-12 
mRNA (Fig. 26) and MMP-9 protein (Fig. 27), indicating that TIMs from MacAMPKα1 
KO mice have higher expression of proinflammatory mediators.  
 We considered a number of downstream targets of AMPKα1 as possible 
mediators of the anti-inflammatory activity we observed. As we had previously observed 
an association of AMPK activity and decreased phosphorylation of p65 NF-κB (Fig. 18), 
we evaluated TIM NF-κB activation through phosphorylation of p65. As shown in Fig. 
28, p65 phosphorylation was significantly higher in TIMs from MacAMPKα1 KO mice 
compared to those from WT mice. Additionally, TIMs from MacAMPKα1 KO mice had 
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significantly decreased expression of p-Akt (Fig. 29A) and p-CREB (Fig. 29B). These 
data demonstrate that TIMs isolated from MacAMPKα1 KO mice have higher 
proinflammatory activity compared to those isolated from WT mice, a factor that may 
contribute to the reduced tumor growth (Figs. 20-21) and lung metastasis (Fig. 22) 





















Figure 20. MacAMPKα1 KO mice have decreased rate of LLC tumor growth. 
MacAMPKα1 KO and WT mice were injected subcutaneously with LLC tumor cells (2 x 
105) and growth was measured every 2-3 days for 18 days using caliper measurements. 
Tumor volume was calculated using the formula (long side x short side2) x 6/π. Data are 
mean ± SEM of results combined from two independent experiments, with 5-7 mice per 















Figure 21. Tumors harvested from MacAMPKα1 KO mice weigh less than those 
from WT mice. MacAMPKα1 KO and WT mice were injected subcutaneously with LLC 
tumor cells (2 x 105) and tumors were harvested 18 days later and weighed. Data are 
mean ± SEM of results combined from two independent experiments, with 5-7 mice per 
















Figure 22. Lungs from MacAMPKα1 KO mice have reduced lung metastases. 
MacAMPKα1 KO and WT mice were injected subcutaneously in the flank with LLC 
tumor cells and lung metastasis was assessed 18 days later. Lungs were perfused and 
stained with Bouin’s solution to visualize metastases. Representative lungs were 
photographed (A) and lung metastases were counted (B). Images in A are representative 
of two separate experiments with similar results and five or more mice in each group. For 
B, data are expressed as mean ± SEM of results combined from two independent 
experiments, with 5-7 mice per group in each experiment (*, p < 0.05).  
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Figure 23. MacAMPKα1 KO and WT mice maintain weight throughout tumor 
growth and metastasis. All mice were injected subcutaneously with LLC tumor cells (2 
x 105) on day 0 and the weight of each mouse was taken every 2-3 days until day 18 (A). 
Average weights of each strain were calculated over time (B). Data are representative of 









Figure 24. MacAMPKα1 KO mice have increased CD19+ and decreased CD8+ 
immune cell infiltration of primary tumors. Single cell suspensions of primary tumors 
isolated from MacAMPKα1 KO and WT mice were generated and expression of various 
immune cell markers was evaluated via flow cytometry. The number of positively stained 
cells in a sample of 10,000 tumor cells was determined and is expressed as a percentage 
(A). The number of positively stained cells in the total tumor was determined and is 
expressed as cell number (B). Data are expressed as mean ± SEM and are the combined 





Figure 25. TIMs isolated from MacAMPKα1 KO mice have decreased expression of 
AMPKα. TIMs were isolated from primary tumors of MacAMPKα1 KO and WT mice. 
After cell lysis, Western blot was performed using Abs against p-AMPKα (Thr172), total 
AMPKα, and β-actin. Data shown are representative of two experiments of five mice per 















Figure 26. TIMs isolated from MacAMPKα1 KO mice have higher expression of 
proinflammatory cytokines and MMP-12 than WT mice. TIMs were isolated from 
primary tumor cell suspensions and mRNA expression was evaluated via RT-PCR and is 
expressed as fold difference compared to TIMs isolated from WT mice. Data expressed 
are from individual mice and are representative of two experiments with similar results 














Figure 27. TIMs isolated from MacAMPKα1 KO mice have increased MMP-9 
expression. TIMs were isolated from primary tumors of MacAMPKα1 KO and WT 
mice. After cell lysis, Western blot was performed using Abs against MMP-9 and β-actin. 
Each band is TIM protein expression from one mouse (A). Densitometric analysis was 
performed and the average MMP-9 / β-actin protein expression for MacAMPKα1 and 
WT TIMs was determined (B). Data shown are representative of two experiments of four 










                                  
 
Figure 28. TIMs isolated from MacAMPKα1 KO mice have increased 
phosphorylation of NF-κB p65. TIMs were isolated from primary tumors of 
MacAMPKα1 KO and WT mice. After cell lysis, Western blot was performed using Abs 
against p-NF-κB p65 (Ser536) and total NF-κB p65. Each band is TIM protein 
expression from one mouse (A). Densitometric analysis was performed and the average 
p-p65 / p65 / β-actin protein expression for MacAMPKα1 and WT TIMs was determined 
(B). Data shown are representative of two experiments of four to five mice per group (**, 











Figure 29. TIMs isolated from MacAMPKα1 KO mice have decreased 
phosphorylation of Akt and CREB. TIMs were isolated from primary tumors of 
MacAMPKα1 KO and WT mice. After cell lysis, Western blot was performed using Abs 
against p-Akt (Ser473) and total Akt (A), p-CREB (Ser133) and total CREB (B), and β-
actin. Each band is TIM protein expression from one mouse (A-B). Densitometric 
analysis was performed and the average p-Akt / Akt (C) and p-CREB / CREB (D) protein 
expression for MacAMPKα1 and WT TIMs was determined. Data shown are 





 Macrophages display remarkable plasticity and can exhibit a number of functional 
phenotypes [120, 226]. TIMs are often found in high number in tumors [227] and usually 
indicate a poor prognosis [191]. TIMs often exhibit an anti-inflammatory, pro-tumor 
phenotype that is shaped by mediators found within the tumor microenvironment and 
TIMs are considered a major obstacle to the development of cancer therapeutics [120]. 
Despite the significant effects of macrophage polarization on tumor biology, the 
molecular and transcriptional mediators that control the pro-tumor phenotype of TIMs 
remain largely unknown.  
Activation of AMPK has been a therapeutic strategy for the treatment of cancer 
for some time. Interest in AMPK activation for tumor therapy began with the discovery 
that LKB1, a known tumor suppressor, is an upstream kinase required for AMPK 
activation [20]. AMPK activation for cancer therapy is supported by the observation that 
diabetic patients treated with metformin have a decreased lifetime cancer risk [83]. 
Studies in tumor mouse models utilizing AICAR and metformin have shown an 
association of AMPK activation and decreased tumor growth [81, 84, 85]. It has been 
reported that AMPK activation is not beneficial in all cancers, however, including some 
oncogene-driven melanomas [228] and prostate cancers [89, 90], suggesting that the role 
of AMPK in cancer development is more complicated than originally thought. Very little 
is known about the contribution of immune cell-expressed AMPKα1 to tumor growth and 
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metastasis. Our studies herein demonstrate that AMPKα1 activity in myeloid cells 
contributes to the anti-inflammatory phenotype of TIMs and is associated with increased 
tumor growth. We are not aware of any other study evaluating the role of AMPKα1 in 
TIM promotion of tumor growth. 
 Mice deficient in myeloid-expressed AMPKα1 had significantly decreased tumor 
growth from days 14-18 post tumor injection (Fig. 20) and TIMs isolated from these mice 
displayed significantly higher proinflammatory cytokine mRNA compared to control 
mice (Fig. 26). In many cancers, TIMs exhibit deficient expression of NF-κB leading to 
impaired iNOS expression and nitric oxide production [229, 230]. Additionally, it has 
been observed that TIMs have very high nuclear localization of the NF-κB inhibitory p50 
homodimer [231] and defective NF-κB activation in response to LPS and TNFα 
stimulation [232]. We observed drastically higher NF-κB p65 activity in TIMs isolated 
from MacAMPKα1 KO mice (Fig. 28), indicating that AMPKα1 inhibition alters TIM 
gene transcription. Additionally, AMPKα1-deficient TIMs displayed decreased activation 
of Akt and CREB (Fig. 29).  These data fit with our previous observations that AMPKα1 
activation is positively correlated with activation of Akt and increased phosphorylation of 
CREB (Fig. 19, [106]). Enhanced CREB activity allows CREB to compete for the 
nuclear coactivator CREB-binding protein and leads to reduced activation of NF-κB.  
Our studies of LLC tumor growth address tumor growth until 18 days post-
injection, when mice were sacrificed. We did not measure tumor growth beyond 18 days, 
and thus it is possible that tumors in MacAMPKα1 KO mice had delayed growth, and 
may eventually catch up to the tumor growth observed in WT mice. Additionally, we did 
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not complete survival studies and it is unknown if MacAMPKα1 KO mice have increased 
survival associated with LLC tumor growth compared to WT.  
Mice with AMPKα1-deficient macrophages had reduced lung metastasis 
compared to control mice (Fig. 22). Macrophages are important in the development of 
lung metastasis, and have been shown to condition pre-metastatic tissue for the seeding of 
metastatic cancer cells [120]. In some tumor models, infiltrating myeloid cells form 
clusters in pre-metastatic tissue, forming what has been termed a “pre-metastatic niche” 
[233, 234]. Our studies show that deficiency of macrophage-expressed AMPKα1 results 
in decreased lung metastasis. However, the functional phenotype of AMPKα1-deficient 
macrophages in the lung is unknown. Furthermore, the role of macrophage-expressed 
AMPKα1 on formation of the pre-metastatic niche still needs to be investigated.   
Our studies indicate no difference in immune cell infiltration of NK, CD4+, CD8+, 
macrophages, and CD11c+ cells in tumors from MacAMPKα1 KO and WT mice (Fig. 
24). Our results did indicate that there was higher infiltration of CD19+ cells in tumors of 
mice deficient of myeloid AMPKα1. Studies suggest that B cells can contribute to the 
immunosuppressive phenotype exhibited by TIMs [235, 236]. B1 cells have been shown 
to polarize peritoneal macrophages to an anti-inflammatory phenotype via IL-10 
expression [235]. Additionally, B cells have been shown to foster angiogenic and pro-
tumor TIM activities through FcRγ-mediated activation [236]. Much is still unknown 
regarding the roles of various B cell populations on determination of TIM phenotype. 
Additionally, how deficiency of myeloid-AMPKα1 leads to enhanced B cell recruitment 
to the tumor still needs to be investigated. One possible explanation is that the tumor 
recruits B cells in an attempt to establish a pro-tumor immunosuppressive environment 
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and combat the higher pro-inflammatory phenotype exhibited by AMPKα1-deficient 
TIMs.   
Functional studies are also required to determine if AMPKα1 activity in TIMs 
affects the role of B cells in the tumor, as well as the roles of other infiltrating immune 
subsets. It is unknown if TIM-expressed AMPKα1 regulates infiltration of Th subsets and 
Treg, which are known to foster the immunosuppressive environment in tumors [237]. 
We observed increased CD8+ T cell infiltration in WT tumors compared to MacAMPKα1 
KO tumors (Fig. 24) and it is unknown how AMPKα1 TIM expression contributes to this 
accumulation and how these cells are functionally contributing to tumor growth.  
It is important to note that because our TIM isolation included positive selection 
of CD11b+ tumor-infiltrating cells, we expect to have tumor-infiltrating MDSC in our 
“TIM” population. As we saw increased proinflammatory activity in tumor-infiltrating 
CD11b+ cells, our studies suggest that MDSC may have a more proinflammatory 
phenotype in MacAMPKα1 KO tumors. A more specific isolation is needed in order to 
distinguish the MDSC functional phenotype from that of CD11b+ TIMs in MacAMPKα1 
KO tumors compared to WT tumors. Additionally, MDSC have a critical role in the 
establishment of the immunosuppressive tumor microenvironment and future studies will 
address the effect of myeloid-AMPKα1 deficiency on recruitment of MDSC to the tumor 
and their functional phenotype within the tumor.  
The immunosuppressive tumor microenvironment is considered a major obstacle 
to the success of cancer therapies.  Herein, we demonstrate that AMPKα1 depletion in 
TIMs critically affects their anti-inflammatory phenotype and their efficiency in 
promoting LLC tumor growth. Our results indicate the therapeutic potential of AMPKα1 
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inhibition as a way to curtail the pro-tumor functions of TIMs and reduce tumor 
progression. Furthermore, these data suggest that efforts to treat cancer through activation 
of AMPKα1 may detrimentally contribute to TIM immunosuppressive phenotype and 
tumor growth.  
AMPK activation has been associated with both reduced risk of cancer 
development and tumor regression [1]. Many AMPK activators, including metformin 
[83], green tea [239], and resveratrol [240] have been shown to reduce cancer risk. The 
association of AMPK activation with reduced risk of specific cancers in various 
populations is still being investigated. It has been shown that metformin leads to reduced 
risk of breast cancer in female diabetic patients [241]. Chronic inflammation has been 
associated with increased cancer incidence, and it is possible that AMPK is inhibiting 
cancer development through decreasing inflammation [1]. Activation of AMPK has been 
shown to also reduce tumor growth, an effect attributed to AMPK inhibition of anabolic 
signaling pathways responsible for cell growth [88]. In conditions of limited energy 
supply, as is often in the tumor microenvironment, AMPK is activated and inhibits 
mTOR activity [67, 242] and lipid synthesis [243, 244], leading to decreased cancer cell 
growth. In addition to AMPK’s role in the metabolism of cancer cells, it also likely has 
an important role in the regulation of metabolism and inflammation of other cells present 
in the tumor. Our results herein demonstrate that AMPKα1 activity in macrophages 
contributes to TIM anti-inflammatory activity and tumor growth. These results suggest 
that AMPKα1’s role in the tumor may be complicated, and that its activation may 
enhance pro-tumor activities in some cells and anti-tumor activities in others. Perhaps 
this is not surprising, as the cellular metabolism of transformed cells may be different 
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than infiltrating immune cells and, accordingly, AMPK regulation of inflammatory and 
metabolic pathways may result in differential regulation of these cell types. 
It is likely that AMPK plays different roles in the stages of tumor development 
and progression, reflecting the complicated nature of the relationship between 
metabolism, inflammation, and cancer. AMPK activation may be beneficial in the 
prevention of cancer pathologies associated with chronic inflammation, while in later 
stages of cancer progression, it may detrimentally contribute to TIM anti-inflammatory 
activity and LLC tumor growth. AMPK inhibition in TIMS may be a valuable therapeutic 
strategy to overcome the strong immunosuppression these cells generate. The use of 
nanoparticle technology may be of potential use to inhibit AMPK in macrophages, 
specifically through utilization of the mannose receptor for macrophage specificity and 
an AMPK inhibitor, such as compound C. Much remains to be investigated, but our 
studies demonstrate that it will important to consider the effect of AMPKα1 activation in 






CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 DCs and macrophages are heterogeneous cells that are involved in both protective 
and pathological immune responses. Understanding the mechanisms that govern their 
behavior is critical to the understanding and development of effective therapies to treat 
many diseases, including autoimmunity and cancer. AMPK has been recognized recently 
as a counter-regulator of inflammatory pathways including those induced by TLR and 
IFNγ stimulation [96, 106, 163] and fatty acids [107, 108]. Through studies on 
macrophage cell lines expressing CA and DN forms of AMPKα1, our lab previously 
reported that AMPKα1 inhibits TLR-mediated inflammatory activity [106]. Herein, we 
have used AMPKα1-deficient primary cells to evaluate the role of AMPKα1 in APC-T 
cell interactions. Our studies show that deficiency of AMPKα1 results in enhanced APC 
inflammatory activity in response to LPS and CD154 stimulation (Fig. 5 and Fig. 16) and 
contributes to the development of proinflammatory Th1 and Th17 responses (Fig 8-10). 
Additionally, we evaluated the role of myeloid cell-expressed AMPKα1 in TIM anti-
inflammatory activity and its contribution to tumor growth. We demonstrate that 
inhibition of AMPKα1 in TIMs enhances their proinflammatory activity (Fig. 26-29) and 
results in decreased tumor growth and lung metastasis (Fig. 20-22). Together, our studies 
of AMPKα1 in antigen presentation and on AMPKα1 in tumor-macrophage interactions 
demonstrate that AMPK is a potent counter-regulator of myeloid inflammatory activity 
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and its activation induces changes in many aspects of myeloid function. These changes 
are mediated through differential regulation of NF-κB and Akt - GSK3β – CREB 
pathways. 
Our results demonstrate a counter-regulatory role for AMPKα1 in the regulation 
of myeloid cell and T cell proinflammatory activity. Much is still unknown regarding the 
role of AMPKα1 in the regulation of immunity. AMPKα1 may have regulatory roles 
regarding the inflammatory activity of other immune cells in addition to macrophages 
and T cells, and this still needs to be investigated. Additionally, a recent report showed 
that AMPKβ1 leads to an 85% reduction in AMPK activity and counter-regulates 
macrophage proinflammatory activity and insulin resistance [108]. Much is still unknown 
regarding the role of AMPKβ1 in the regulation of macrophage inflammation and the role 
of AMPKβ1 in antigen presentation activities still needs to be investigated.  
Our studies and others have identified AMPKα1 is a counter-regulator of 
macrophage and DC inflammatory activity and both activation and inhibition of AMPK 
may be valuable therapeutic strategies for inflammatory diseases (Fig. 30). Excessive 
Th1 and Th17 responses are associated with autoimmune disease and research strategies 
include identifying targets that can attenuate these T cell responses. Our results indicate 
that AMPKα1 is one such potential target, as AMPKα1 expression in both APC and T 
cells leads to reduced IFNγ and IL-17 T cell production in antigen presentation assays 
(Figs. 6, 8-9, 30). Indeed, it has been shown that AMPK activation ameliorates 
experimental mouse models of autoimmunity, including EAE [98] and EAU [43]. 
Chronic inflammation has been long associated with increased risk for several cancers, 
including lung, and activation of AMPK may reduce systemic inflammation and risk for 
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these cancers (Fig. 30). Importantly, the effectiveness of AMPK activation on the 
prevention of cancer development may be dependent on the type of cancer and the timing 
of treatment or stage of cancer development. There are several readily available 
pharmacological and dietary activators of AMPK, as discussed in Chapter 1. 
The therapeutic use of inhibitors of AMPKα1 activity also may be worthwhile, as 
there are many diseases where an immunosuppressive environment perpetuates 
pathology, such as cancer (Fig. 30). Our studies on TIMs from MacAMPKα1 KO mice 
indicate that in cancer, inhibition of AMPKα1 activates a proinflammatory immune 
response in TIMs that leads to reduced tumor growth. Inhibition of AMPKα1 in TIMs 
may be a valuable therapeutic strategy to combat immunosuppressive TIMs that 
contribute to tumor growth (Fig. 30). Inhibition of AMPKα1 in DCs may also be a 
valuble strategy to combat the tolerogenic phenotype known to be an obstacle to DC 
vaccine immunotherapy. It is also possible that inhibition of AMPKα1 may also lead to a 
more potent anti-microbial and/or anti-parasite immune response, although this has not 
been tested (Fig. 30). 
This study is the first to identify AMPKα1 as a mediator of TIM anti-
inflammatory activity. TIMs isolated from MacAMPKα1 KO mice had increased 
phosphorylation of p65 NF-κB (Fig. 28) and expressed higher levels of IL-6 and TNFα 
mRNA (Fig. 26). Higher expression of proinflammatory markers in TIMs was associated 
with decreased tumor growth. TIMs have a critical role in the development of the 
immunosuppressive, pro-tumor environment and identifying mediators of TIM anti-
inflammatory activity, such as AMPK, is critical for the development of cancer 
immunotherapies. Additionally, the extent of myeloid AMPKα1’s influence on the pro- 
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and anti-tumor functions of other immune cell populations within the tumor, including 
cytotoxic T cells, Treg, and MDSC still needs to be investigated. It is unknown if 
AMPKα1 also plays a counter-regulatory role in the inflammatory activity of tumor 
infiltrating T cells. Our laboratory has mice deficient in CD4 cell-expressed AMPKα1 
that could be utilized to determine the role of AMPKα1 in CD4+ cells in tumor growth 
and metastasis.  
The anti-inflammatory effect of AMPK on leukocyte behavior has been 
associated with the involvement of AMPK in cellular metabolism. Recent reports suggest 
that AMPK represses the metabolic switch from oxidative phosphorylation to glycolysis 
that occurs when cells become inflammatory. As described in two recent reviews from 
the lab of Graham Hardie [93, 245], resting and naïve immune cells generally use 
oxidative phosphorylation to generate ATP and when stimulated with proinflammatory 
stimuli (cytokines, TLRs, antigen presentation), switch to aerobic glycolysis for 
generation of ATP [94-96]. It has been observed that treatment with a glycolytic inhibitor 
causes proinflammatory Th17 cells to exhibit qualities more like anti-inflammatory 
Tregs, suggesting that metabolic cues are involved in the regulation of the glycolytic 
switch [94]. It is thought that increased rates of glycolysis provide a swift, yet inefficient, 
source of energy for the cell to become more inflammatory. AMPK activation through 
AICAR antagonizes the LPS-induced switch to glycolysis in DCs [96]. Additionally, T 
cells isolated from AMPKα1-/- mice display elevated levels of glycolysis [116]. AMPK 
inhibits protein synthesis through TORC1 [67, 68], and it has been proposed that AMPK 
mediates the glycolytic switch through repressing expression of the transcription factor 
hypoxia-inducible factor-1α (HIF1α) through TORC1 inhibition [245]. HIF1α expression 
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drives the production of glycolytic enzymes and its inhibition could then repress the 
glycolytic switch [245].   
Our findings regarding AMPKα1’s role in regulation of myeloid inflammatory 
activity raise many questions regarding the role of AMPKα1 in regulation of the 
glycolytic switch. AMPKα1 antagonizes CD154-induced proinflammatory signaling and 
cytokine production and it is unknown if CD154 stimulation is associated with a 
transition from oxidative to glycolytic metabolism. Additionally, AMPKα1’s ability to 
suppress the switch to glycolysis in response to CD154 still needs to be investigated.  Our 
studies show that AMPKα1 regulates the anti-inflammatory activity in TIMs and it is 
unknown if AMPKα1 represses glycolytic activity in TIMs and thereby contributes to 
their anti-inflammatory phenotype. The metabolic switch to glycolysis was first observed 
in proliferating cancer cells and was termed the ‘Warburg effect,’ and the potential ability 
of AMPKα1 to induce an anti-Warburg effect in cancer is one argument for using AMPK 
activators to treat cancer patients [245].  
As we learn more about the metabolic profile of tumor-infiltrating immune cell 
subsets, it will be important to consider the impact AMPKα1 activation may have on their 
inflammatory phenotype and role in the tumor microenvironment. It is also important to 
consider that aside from its regulatory role in cell metabolism, AMPKα1 activity 
modulates numerous signaling pathways that influence cell behavior and gene 
transcription. Given its clear role in the regulation of both metabolism and inflammation, 






Figure 30. Both activation and inhibition of myeloid AMPKα1 may be useful 
therapeutic strategies. Activation of AMPKα1 in myeloid cells leads to decreased pro-
inflammatory activity including increased Akt - GSK3β – CREB signaling and IL-10 
production. AMPKα1 activation may be a useful therapeutic strategy for the treatment of 
diseases exacerbated by inflammation, such as autoimmune disease cancer-causing
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chronic inflammation. Inhibition of AMPKα1 activity in myeloid cells leads to increased 
proinflammatory activity including increased Th1 and Th17 T cell responses, NF-κB and 
MAPK signaling, costimulatory molecule expression, and IL-6 and TNF-α cytokine 
production. AMPKα1 inhibition may be a useful therapeutic strategy to increase the 
inflammatory activity of immunosuppressive TIMs and tolerogenic DC in vaccine 
immunotherapy. Additionally, AMPKα1 inhibition may lead to a more potent anti-
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